



BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Emergency Department presentations related to asthma and allergic diseases in Central Queensland, Australia: a comparative analysis between First Nations Australians and Australians of other descents

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2024-091482
Article Type:	Original research
Date Submitted by the Author:	23-Jul-2024
Complete List of Authors:	<p>Shifti, Desalegn Markos; The University of Queensland, Child Health Research Centre, ; Murdoch Children's Research Institute, Centre for Food and Allergy Research (CFAR)</p> <p>Al Imam, Mahmudul Hassan ; Central Queensland Hospital and Health Service, Central Queensland Public Health Unit</p> <p>Maresco-Pennisi, Diane; The University of Queensland, Centre for Clinical Research</p> <p>Whitcombe, Renarta; Central Queensland Hospital and Health Service, Central Queensland Public Health Unit,</p> <p>Sly, P.D.; The University of Queensland, Children's Health and Environment Program, Child Health Research Centre</p> <p>Munns, Craig; The University of Queensland, Child Health Research Centre; The University of Queensland, Faculty of Medicine</p> <p>Peters, Rachel ; Murdoch Children's Research Institute; University of Melbourne, Department of Paediatrics</p> <p>Khandaker, Gulam; The University of Queensland, Child Health Research Centre; Central Queensland Hospital and Health Service, Central Queensland Public Health Unit</p> <p>Koplin, Jennifer J; The University of Queensland, Child Health Research Centre; Murdoch Children's Research Institute, Centre for Food and Allergy Research (CFAR)</p>
Keywords:	Chronic Disease, EPIDEMIOLOGIC STUDIES, EPIDEMIOLOGY, Prevalence, Asthma < THORACIC MEDICINE, Emergency Service, Hospital

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

**Emergency Department presentations related to asthma and allergic diseases in Central Queensland, Australia: a comparative analysis between First Nations Australians and Australians of other descents**

**Authors:** Desalegn Markos Shifti<sup>a,b</sup>, PhD, Mahmudul Hassan Al Imam<sup>c</sup>, PhD, Diane Maresco-Pennisi<sup>d</sup>, PhD, Renarta Whitcombe<sup>e</sup>, GDip, Peter D Sly<sup>e</sup>, MD, DSc, Craig F Munns<sup>a,f,g</sup>, PhD, Rachel L Peters<sup>h,i</sup>, PhD, Gulam Khandaker<sup>a,c</sup>, PhD, Jennifer J Koplin<sup>a,b,h</sup>, PhD

**Affiliations:**

<sup>a</sup>Child Health Research Centre, The University of Queensland, South Brisbane, QLD, Australia

<sup>b</sup>Centre for Food and Allergy Research (CFAR), Murdoch Children's Research Institute, Parkville, VIC, Australia

<sup>c</sup>Central Queensland Public Health Unit, Central Queensland Hospital and Health Service, Rockhampton, QLD, Australia

<sup>d</sup>Centre for Clinical Research, The University of Queensland, Brisbane, QLD, Australia

<sup>e</sup>Children's Health and Environment Program, Child Health Research Centre, The University of Queensland, South Brisbane, Australia

<sup>f</sup>Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia

<sup>g</sup>Department of Endocrinology and Diabetes, Queensland Children's Hospital, Brisbane, QLD, Australia

<sup>h</sup>Murdoch Children's Research Institute, Parkville, VIC, Australia

<sup>i</sup>Department of Paediatrics, University of Melbourne, Parkville, Australia

**Email address:**

Desalegn Markos Shifti: [d.shifti@uq.edu.au](mailto:d.shifti@uq.edu.au)

Mahmudul Hassan Al Imam: [mahmudul.alimam@health.qld.gov.au](mailto:mahmudul.alimam@health.qld.gov.au)

Diane Maresco-Pennisi: [d.marescopennisi@uq.edu.au](mailto:d.marescopennisi@uq.edu.au)

Renarta Whitcombe: [Renarta.Whitcombe@health.qld.gov.au](mailto:Renarta.Whitcombe@health.qld.gov.au)

Peter D Sly: [p.sly@uq.edu.au](mailto:p.sly@uq.edu.au)

Craig F Munns: [c.munns@uq.edu.au](mailto:c.munns@uq.edu.au)

Rachel L Peters: [rachel.peters@mcri.edu.au](mailto:rachel.peters@mcri.edu.au)

Gulam Khandaker: [gulam.khandaker@health.qld.gov.au](mailto:gulam.khandaker@health.qld.gov.au)

Jennifer J Koplin: [j.koplin@uq.edu.au](mailto:j.koplin@uq.edu.au)

**Corresponding author:** Desalegn Markos Shifti. Email: [d.shifti@uq.edu.au](mailto:d.shifti@uq.edu.au); Level 6, 62 Graham Street, South Brisbane, QLD 4101, Australia.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Abstract**

**Objective:** To examine the overall incidence rate and trends in Emergency Department (ED) presentations related to asthma and allergic diseases in regional Australia with a particular focus on First Nations Australians.

**Design:** A retrospective analysis of data from the Emergency Department Information System.

**Setting:** This study used data from 12 public hospitals in Central Queensland, Australia, a region encompassing regional, rural, and remote outback areas.

**Participants:** A total of 813,112 ED presentations between 2018 and 2023.

**Outcome measure:** Asthma and allergic diseases were identified using the International Classification of Diseases-Tenth Revision-Australian Modification (ICD-10-AM) codes.

**Results:** There were 13,273 asthma and allergic disease-related ED presentations, with an overall prevalence of 1.6% (95% confidence interval (CI): 1.6, 1.7). There was a significantly higher incidence rate of asthma and allergic disease-related ED presentations among First Nations Australians at 177.5 per 10,000 person-years (95% CI: 169.3, 186.0), compared to 98.9 per 10,000 person-years (95% CI: 97.2, 100.8) among Australians of other descents. The incidence rates, with corresponding 95% CI, of the four most common cases among First Nations Australians and Australians of other descents, respectively, were as follows: asthma (87.8 (82.0, 93.8) and 40.2 (39.0, 41.3)), unspecified allergy (55.3 (50.8, 60.2) and 36.0 (34.9, 37.1)), atopic/allergic contact dermatitis (17.1 (14.6, 19.9) and 10.6 (10.0, 11.2)), and anaphylaxis (7.2 (5.6, 9.1) and 6.2 (5.7, 6.6)).

**Conclusion:** Our findings highlight a significantly higher rate of asthma and allergic disease-related ED presentations among First Nations Australians compared to Australians of other descents. This underscores the urgent need for targeted healthcare interventions integrating culturally appropriate approaches, alongside additional research to understand causality.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

**Keywords:** Allergic diseases; Asthma; First Nations Australians; Indigenous Australians; Aboriginal and Torres Strait Islander peoples; Australians of other descents; Emergency Department, Trend, Incidence, Central Queensland, Australia

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Strengths and limitations of the study**

- The study uses the most recent, large data set including First Nations Australians and Australians of other descents and all age groups from a study setting encompassing regional, rural, and remote outback areas.
- The reporting of ED presentations related to asthma and allergic disease relies on the ICD codes entered by physicians at the time of presentation.
- Our study specifically focused on asthma and allergic disease-related ED presentations and did not encompass all instances of acute asthma and allergic diseases in the general population which may visit health facilities in routes other than ED.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

## Introduction

Chronic diseases including asthma and allergy, are a leading cause of premature death and morbidity globally<sup>1 2</sup> and constitute a growing public health concern.<sup>3-5</sup> It is estimated that by 2050, 50% of the world's population will be affected by allergies.<sup>1 6</sup> In Australia, often labelled as the 'allergy capital of the world',<sup>7</sup> allergy is currently estimated to affect 4.1 million people and is anticipated to undergo a 70% surge, with affected individuals projected to reach 7.7 million (26.1%) by 2050.<sup>3</sup>

Allergic diseases exert considerable economic and social impact and negatively impact individuals' and families' day-to-day living as well as quality of life.<sup>8 9</sup> The overall economic cost of food allergy alone in the United States was estimated to be USD 24.8 billion annually or USD 4184 per child.<sup>10</sup> The total Medicare cost for out-of-hospital services related to food allergy in children aged 1 to 4 years in Melbourne, Australia alone was estimated at AUD 26.1 million annually.<sup>11</sup>

There are clear racial, ethnic, and socioeconomic disparities in allergic diseases worldwide.<sup>12-14</sup> Studies conducted on the burden of allergic disease in racially and ethnically structurally oppressed communities in Canada and the United States (US) showed an increased burden of allergic and atopic diseases among the Indigenous peoples of Canada.<sup>15 16</sup> Specifically, studies<sup>15 16</sup> reported a significantly higher prevalence of current eczema (25% among Indigenous children compared to 14.3% among non-Indigenous children), current allergic rhinitis (12.5% among Indigenous children compared to 0.0% among non-Indigenous children), environmental allergy (4.2% among Indigenous and 0.0% among non-Indigenous), and past asthma (16.7% among Indigenous children compared to 14.2% among non-Indigenous children). However, little is known about the prevalence of allergies and anaphylaxis in First Nations Australians.<sup>17</sup> In our study, the phrase 'First Nations Australians' respectfully refers to the Aboriginal and Torres Strait Islander peoples in Australia.<sup>18</sup>

In general, the burden of disease is 2.3 times higher among First Nations Australians,<sup>19</sup> and health outcomes are poorer when compared to Australians of other descents.<sup>20</sup> Asthma was the third most commonly reported long-term condition (16%) affecting First Nations Australians,<sup>21 22</sup> and First



1  
2  
3 101 Nations Australian children had a 2.3 times higher prevalence of asthma than Australian children of  
4  
5 102 other descents.<sup>23</sup> However, there has been little research into other types of allergic disease in First  
6  
7 103 Nations Australians.  
8  
9  
10 104 Existing evidence from other countries suggests that disparities in the prevalence of allergic diseases  
11  
12  
13 105 exist between rural and urban areas. For example, a study conducted in South Africa reported a higher  
14  
15 106 prevalence of self-reported allergies and a higher prevalence of objectively measured food allergy in  
16  
17 107 urban areas compared to rural areas.<sup>24 25</sup> This underscores the importance of conducting region-  
18  
19 108 specific studies to inform targeted interventions and healthcare strategies. There has been little  
20  
21  
22 109 research into allergic disease in regional and rural areas of Australia. The lack of comprehensive data  
23  
24 110 in these areas hinders our understanding of the unique factors influencing allergies in regional  
25  
26 111 settings, including distinct environmental exposures and lifestyle variations. Although some  
27  
28 112 evidence<sup>26</sup> suggests that certain allergies, including food allergies and eczema, may be less common  
29  
30 113 in Northern Australia based on self-report, region-specific further studies are required to inform  
31  
32  
33 114 targeted interventions and healthcare strategies.  
34  
35  
36 115 The current study endeavours to fill some of the existing evidence gaps by examining incidence rate  
37  
38 116 and trends of ED presentations related to asthma and allergic diseases, both collectively and  
39  
40 117 individually, among both First Nations Australians and Australians of other descents in Central  
41  
42  
43 118 Queensland, which encompasses both regional and rural and remote areas, from 2018 to 2023.

44  
45 119 **Methods**

46  
47  
48 120 We conducted a retrospective analysis of data from the Emergency Department Information System  
49  
50 121 (EDIS) of Public Hospitals in Central Queensland (CQ), a regional district of Queensland, Australia,  
51  
52 122 located in the central east region (the study area map can be found in online Supplemental Figure 1  
53  
54 123 1).<sup>27</sup> The map was developed using the digital boundary files from the Australian Bureau of Statistics.<sup>28</sup>  
55  
56  
57 124 CQ encompasses rural and remote outback towns.<sup>29</sup> This analysis focused on the service catchment  
58  
59  
60 125 area of Central Queensland Hospital and Health Service (CQHHS) and included all patients presenting

to the emergency department. CQHHS operates 12 public hospitals across various regions. These include 1) Rockhampton, Mount Morgan, and Capricorn Coast, situated within Inner Regional Australia, 2) Gladstone, Biloela, Emerald, Baralaba, Moura, Theodore, and Blackwater, which fall under Outer Regional Australia, and 3) Woorabinda and Springsure, located in Remote Australia.<sup>30 31</sup> CQHHS also provides Aboriginal and Torres Strait Islander Health, Maternity services, CQ Cancer Care Services, Mental Health, Alcohol and Other Drugs Services, Oral Health and General Practitioner referrals.<sup>30</sup> In this analysis, we used data only from ED presentations. Data from the 2021 national census show that the CQ region was populated by 228,246 people.<sup>32</sup> There were 59,070 families in CQ; the median age was 38 years and 64% of the population was aged between 15–64 years.<sup>32</sup> Over seven per cent (7.2%) of the total population in CQ identify as First Nations Australians.<sup>32</sup>

We identified ED presentations related to asthma and allergic disease by using the International Classification of Diseases-Tenth Revision-Australian Modification (ICD-10-AM) codes, as detailed in Supplemental Table 1. Given that not all asthma cases are necessarily allergic,<sup>33 34</sup> and considering that our dataset encompasses the ICD code J45.9, indicative of unspecified asthma, we presented asthma both independently and collectively with allergic diseases. This approach aims to clarify both the overall burden of asthma and allergic diseases collectively, as well as specific instances.

We described the overall asthma and allergic disease-related ED presentations using covariates available in the administrative data. These were self-reported indigenous status (Aboriginal and/or Torres Strait Islanders, which are categorised into First Nations Australians, and not-Indigenous and not stated, which are categorised into Australians of other descents<sup>35</sup>), sex (female and male and intersex (intersex were combined with male because there were only 106 (0.01%) individuals who identified themselves as intersex), age group in years ( $\leq 4$ , 5-14, 15-29, 30-44, 45-59, 60+), hospital (Baralaba, Biloela, Blackwater, Emerald, Gladstone, Mount Morgan, Moura, Rockhampton, Springsure, Theodore, Woorabinda, and Yeppoon) as indirect indicator of place of residence.

## Data management and statistical analysis

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Data for the period January 2018 to November 2023 were retrieved in a one-time extraction from the data sources, deidentified, replaced with unique codes, and securely stored. We described participants' characteristics using frequency with per cent. P values were calculated using Pearson's  $\chi^2$  test. The incidence rates, with 95% confidence intervals (CIs), assuming a Poisson distribution, were calculated as the number of new asthma and allergic disease-related ED presentations per year divided by the total population of Central Queensland at risk during the same period. The total population of Central Queensland at risk per year was estimated as the total population of Central Queensland as reported by the Australian Bureau of Statistics.<sup>36</sup> The comparison of incidence and trends of asthma and allergic disease-related ED presentations over time was assessed using Poisson regression, presented as incidence rate ratios (IRRs) with corresponding 95% CIs. We used the goodness-of-fit chi-squared test to assess whether the Poisson model adequately fit our data. All P-values for these tests were not statistically significant (data not presented), suggesting that the Poisson model reasonably fits the observed data. Incidence rates specific to overall, indigenous status, and other available covariates, as described above, were presented.

**Patient and public involvement**

Patients and/or the general public were not involved in the design, or conduct, or drafting of this secondary analysis.

**Results**

There were a total of 813,112 ED presentations between January 2018 and November 2023, ranging from 1,248 (0.1%) in Baralaba to 303,138 (37.3%) in Rockhampton (Supplemental Table 2).

**Background characteristics of patients presenting with asthma and allergic diseases**

Table 1 presents the background characteristics of patients presenting to the ED due to asthma and allergic diseases. Statistically significant differences were observed in overall asthma and allergic disease-related ED presentations, with a higher proportion among females (1.8%), children aged

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

175 between 5-14 (2.8%), children aged under five (2.5%), and across various hospital catchment areas  
176 (Table 1).

### 177 **Incidence rates of asthma and allergic disease-related ED presentations**

178 Overall, the rate of asthma and allergic disease-related ED presentations was 96.9 per 10,000 person-  
179 years (95% CI: 95.3, 98.6). There was a higher rate of asthma and allergic disease-related ED  
180 presentations among the First Nations Australians, which was 177.5 per 10,000 person-years (95% CI:  
181 169.3, 186.0), compared to the incidence rate among Australians of other descents, which was 98.9  
182 per 10,000 person-years (95% CI: 97.2, 100.8).

183 Table 2 illustrates the incidence rate of the specific case between 2018 and 2023. The four most  
184 common cases presenting to emergency departments were asthma (40.5/10,000 person-years, 95%  
185 CI: 39.4, 41.5), unspecified allergy (34.6/10,000 person-years, 95% CI: 33.6, 35.6), atopic/allergic  
186 contact dermatitis (10.3/10,000 person-years, 95% CI: 9.7, 10.8) and anaphylaxis and anaphylactic  
187 shock (5.8/10,000 person-years, 95% CI: 5.4, 6.2). There was a higher incidence rate of asthma,  
188 unspecified allergy, atopic/allergic contact dermatitis and allergic urticaria among First Nations  
189 Australians compared to Australians of other descents. No food allergy presentations were reported  
190 in our data (Table 2).

### 191 **Time trend of asthma and allergic disease-related ED presentations**

192 Figure 1 presents the time trend in the rates of asthma and allergic disease-related ED presentations  
193 in Central Queensland. Except for the notable increase observed between 2018 and 2019, collective  
194 asthma and allergic disease-related ED presentations among First Nations Australians remained  
195 relatively stable. These rates ranged from 132.3 per 10,000 person-year (95% CI: 115.3, 151.1) in 2018  
196 to 157.2 per 10,000 person-year in 2023 (95% CI: 138.6, 177.5;  $P=0.462$ ). Similarly, rates of asthma  
197 and allergic disease-related presentations among Australians of other descents were nearly stable,  
198 varying from 94.0 per 10000 person-year (95% CI: 89.8, 98.4) in 2018 and 88.6 per 10000 person-year  
199 (95% CI: 84.5, 92.9,  $p=0.846$ ) in 2023.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure 2 shows the time trend of ED presentation rates related to asthma and allergic disease separately. There was a significant increase in the rate of allergic diseases among First Nations Australians over time ( $P$  value = 0.026). Except for the peak observed in 2019 among First Nations Australians, asthma-related ED presentations remained relatively stable over time in both First Nations Australians and Australians of other descents.

Table 3 presents the total incidence of asthma and allergic disease-related ED presentations over the study period by gender and age group. The incidence rate of asthma and allergic disease-related ED presentations remained stable across indigenous status, gender, and age groups, with one exception. Among children aged 4 years or younger, there was a significant decline in the overall incidence of asthma and allergic disease-related ED presentations (IRR = 0.94, 95% CI: 0.91, 0.97,  $P < 0.001$ ) (Table 3).

**Discussion**

To the best of our knowledge, this is the first study to examine asthma and allergic disease-related ED presentations among both First Nations Australians and Australians of other descents in an understudied region of Australia, which encompasses both rural and remote outback towns. There was a significant increase in the rate of allergic diseases among First Nations Australians between 2018 and 2023. First Nations Australians in CQ experienced a significant rise in allergic diseases, with higher rates of ED presentations compared to Australians of other descents. Asthma, unspecified allergies, atopic/allergic contact dermatitis, and anaphylaxis/anaphylactic shock were the most common conditions observed in the ED presentations, with higher rates among First Nations Australians compared to Australians of other descents.

The higher rate of ED presentations related to allergic disease among First Nations Australians was surprising given that allergic and atopic diseases have not been traditionally recognised as an important concern among First Nations Australians.<sup>37</sup> Nevertheless, there is currently a growing recognition of this issue. Our findings highlight a substantial and potentially increasing burden of

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

allergic disease among First Nations Australians living in a region encompassing regional, rural, and remote outback areas. This finding is in agreement with the findings of a study conducted in Canada and the US that showed an increased burden of allergic and atopic diseases among the Indigenous peoples of Canada.<sup>15</sup> Other previous studies conducted in the US and Australia, while lacking specific data on First Nations populations, also documented the existence of racial, ethnic, and socioeconomic disparities in food allergies.<sup>12-14</sup> Further studies are warranted to understand the underlying causes of these observed disparities.

There was a notable peak in recorded asthma-related ED presentations among First Nations Australians in 2019. This could be partially attributed to the bushfires that swept across Australia in 2019–20, also known as Black Summer, as asthma was one of the primary reasons for the ED presentations. Evidence shows that the national increase in emergency presentation and hospitalisation rates for asthma and chronic obstructive pulmonary disease (COPD) coincided with increased bushfire activity during the 2019–20 bushfire season.<sup>38</sup> Bushfire smoke exposure was significantly associated with an increased risk of respiratory morbidity and other health impacts.<sup>39 40</sup> The notable spike in recorded asthma-related ED presentations could also be ascribed to the notably vigorous flu season in 2019,<sup>41</sup> which is recognised as one of the triggers for an asthma attack.<sup>42</sup>

The primary reason for ED presentations was asthma, with a significantly higher incidence observed among First Nations Australians compared to Australians of other descents. Within our dataset, asthma cases could encompass both allergic and non-allergic variants. Literature documented that First Nations Australians were 1.6 times more likely to report having asthma in 2018-19 compared with Australians of other descents.<sup>43</sup> Another study that used birth, hospital and emergency data for all First Nations Australian children born between 2003 and 2012 in Western Australia reported that 2.7% of children had been hospitalised for asthma at least once between the ages of 1 and 4 years.<sup>44</sup> The higher incidence in asthma related ED presentation could be multifactorial including first time/unrecognised asthma, unmet medical need, unsuccessful/inadequate home management, medication

1  
2  
3 250 non-adherence, exacerbation triggered by environmental factors, including bushfire, environmental  
4  
5 251 pollution, and risky health behaviours such as smoking. Literature has documented that nearly half  
6  
7 252 (47%) of the respiratory disease burden among First Nations Australians in 2018 was linked to  
8  
9 253 smoking.<sup>45</sup> The lack of access to culturally appropriate asthma education and healthcare services could  
10  
11 254 also contribute to the higher incidence of asthma related ED presentations among First Nations  
12  
13 255 Australians.<sup>46</sup>  
14  
15  
16  
17 256 Atopic/allergic contact dermatitis ranked as the third most common cause for ED visits, with a higher  
18  
19 257 rate noted among First Nations Australians compared to Australians of other descents. A 5-year  
20  
21 258 retrospective audit of all outpatient encounters with a visiting dermatology specialist in the Kimberley  
22  
23 259 region of Western Australia reported that eczema/dermatitis was the primary condition seen in First  
24  
25 260 Nations Australians (19%) and third most common in Australians of other descents (17%).<sup>47</sup> Another  
26  
27 261 study conducted in Melbourne between 2009 and 2011 reported that 3.9% of ED presentations were  
28  
29 262 due to skin complaints, of which eczema/dermatitis was the fourth most common dermatological  
30  
31 263 condition although data on the indigenous status of the study population<sup>48</sup> was not reported. It is  
32  
33 264 documented that atopic dermatitis is associated with a higher risk of other atopic disorders, including  
34  
35 265 asthma, hay fever, food allergy, and eosinophilic esophagitis.<sup>49</sup> It is also a known risk factor for  
36  
37 266 streptococcal skin infection<sup>49-52</sup> and subsequent systemic and life-threatening complications including  
38  
39 267 sepsis, endocarditis, and bone and joint infections if left untreated.<sup>49 53-55</sup> For instance, a study at the  
40  
41 268 Wuchopperen Clinic in Cairns, Far North Queensland, found that 73.7% of children and youths treated  
42  
43 269 for skin infections tested positive for group A streptococcus.<sup>56</sup>  
44  
45  
46  
47  
48  
49 270 We found that anaphylaxis/anaphylactic shock was the fourth most common cause of allergy related  
50  
51 271 ED presentations. Previous studies conducted in Australia<sup>57 58</sup> documented an increase in the rate of  
52  
53 272 anaphylaxis over time although they lack data based on indigenous status. A study conducted in  
54  
55 273 Victoria reported that the causes of anaphylaxis-related ED presentations were foods (62%); drugs  
56  
57 274 (12%), insect venoms (8%), and other causes (4%).<sup>59</sup> The current study lacked data to specify the  
58  
59  
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Enseignement Supérieur (ABES)



275 causes of anaphylaxis/ anaphylactic shock. Interestingly, there were no food allergy presentations  
276 recorded in our data. However, it is possible that a substantial portion of the unspecified allergies,  
277 which was the second most frequent cause of ED presentations, may be linked to food allergies.  
278 Further studies are required to fill this evidence gap in our study area.

279 There was a twofold higher rate of allergic urticaria, which ranked as the fifth leading cause of ED  
280 visits, among First Nations Australians compared to their counterparts. A study conducted in Italy  
281 reported that acute urticaria in 1 year accounted for 1.01% of total ED visits and 1.2 admissions per  
282 day<sup>60</sup> and drugs, insect bites, foods and contact urticaria were the most common triggers identified.  
283 With a presumption that allergic urticaria that results in ED presentation in our study is acute urticaria  
284<sup>61</sup>, literature documented its risk factors including high population density,<sup>62</sup> personal<sup>63</sup> and parental  
285 history of allergic diseases,<sup>64 65</sup> poverty and lower socio-economic status.<sup>62 66</sup> Further studies are  
286 required to understand risk factors associated with allergic urticaria, particularly among First Nations  
287 Australians.

288 Strengths of the study include the use of the most recent, large data set including both First Nations  
289 Australians and Australians of other descents and all age groups from a study setting encompassing  
290 regional, rural, and remote outback areas. As a limitation, the reporting of ED presentations related  
291 to asthma and allergic disease relies on the ICD codes entered by physicians at the time of  
292 presentation. Our study specifically focused on asthma and allergic disease-related ED presentations  
293 and did not encompass all instances of acute asthma and allergic diseases in the general population  
294 which may visit health facilities in routes other than ED. Caution should be taken when generalising  
295 our results to the broader population, as they may not fully reflect the overall incidence of asthma  
296 and allergic diseases in the community but asthma and acute allergic disease resulting in ED visits only.  
297 Our analyses were limited to factors available in the administrative data, not comprehensively  
298 incorporating other important factors, including socioeconomic status, which encompasses  
299 education, financial resources, social standing, access to transportation, mobile phones, the internet,



1  
2  
3 300 housing conditions, and geographic location,<sup>67</sup> comorbidities, time of first allergy diagnosis, family  
4  
5 301 history of allergies, obesity/overweight, smoking status, and environmental factors among others. For  
6  
7 302 instance, literature has documented that social disadvantage impacts many aspects of allergic disease,  
8  
9  
10 303 including healthcare access, prevalence, and outcomes.<sup>12 68</sup> Therefore, further research is needed to  
11  
12 304 explore the overall incidence of asthma and allergic diseases, considering a comprehensive set of  
13  
14 305 potential confounders, to provide a more thorough understanding of both overall allergy incidence  
15  
16 306 and its associated factors. Also, it is important to note that our study relied on the accurate reporting  
17  
18  
19 307 of individuals' indigenous status in medical records.

20  
21  
22 308 **Conclusion**  
23  
24 309 Our findings highlight a significantly higher rate of asthma and allergic disease-related ED  
25  
26 310 presentations among First Nations Australians compared to Australians of other descents in Central  
27  
28 311 Queensland. This underscores the urgent need for further research to understand the causality and  
29  
30 312 targeted healthcare interventions integrating a culturally sensitive approach.

31  
32  
33 313 **Acknowledgements**  
34  
35  
36 314 We express our gratitude to Central Queensland Hospital and Health Service (CQHHS) for granting us  
37  
38 315 permission to use routinely collected hospital administrative data for our further analysis.

39  
40  
41 316 **Contributors**  
42  
43  
44 317 All authors (DMS, MHA, DM, RW, PDS, CFM, RLP, GK, JJK) contributed to the design of the study and  
45  
46 318 the interpretation of data. DMS performed the data analysis and drafted the manuscript. All authors  
47  
48 319 (DMS, MHA, DM, RW, PDS, CFM, RLP, GK, JJK) read, revised, and approved the final manuscript.

49  
50  
51 320 **Funding**  
52  
53  
54 321 PDS (GRT1193840), R.L.P. (GNT1160779), G.K. (2021/GNT2009873), and J.J.K. (GNT1158699) are  
55  
56 322 supported by NHMRC-funded fellowships. This study received no grant from any funding agency in  
57  
58 323 public, commercial or not-for-profit domains.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Enseignement Supérieur (ABES)

324 **Conflict of interest**

325 All other authors declare no conflict of interest.

326 **Patient consent for publication**

327 Not required.

328 **Ethics approval**

329 We obtained ethics approval from the Human Research Ethics Committee (HREC) of the Central  
330 Queensland Hospital and Health Service (CQHHS) (Reference Id: 101806). Owing to the retrospective  
331 design of this study and its reliance on routinely collected hospital administrative data for medical  
332 services, seeking individual consent was deemed unnecessary.

333 **Data availability statement**

334 Data are not publicly available and may be obtained from a third party. Deidentified patient data can  
335 be requested from the Central Queensland Hospital and Health Service (CQHHS).

336 **ORCID iDs**

337 Desalegn Markos Shifti: <https://orcid.org/0000-0001-6638-6194>

References

1. Tanno LK, Demoly P. Allergy in the World Health Organization's International Classification of Diseases (ICD)-11. *Pediatric Allergy and Immunology* 2022;33:5-7.

2. WHO. Noncommunicable diseases [cited 11 April 2024]. Available from: <https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases> accessed 2024 11 April.

3. Cook M, Douglass J, Mallon D, et al. The economic impact of allergic disease in Australia: not to be sneezed at. *ASCIA/Access Economics Report* 2007

4. Vale SL, Said M, Smith J, et al. Welcome back Kotter—developing a national allergy strategy for Australia. *World Allergy Organization Journal* 2022;15(11):100706.

5. Nunes C, Pereira AM, Morais-Almeida M. Asthma costs and social impact. *Asthma research and practice* 2017;3:1-11.

6. Papadopoulos NG, Agache I, Bavbek S, et al. Research needs in allergy: an EAACI position paper, in collaboration with EFA. *Clinical and translational allergy* 2012;2(1):1-23.

7. Parliament of Australia. Overview of allergies and anaphylaxis in Australia [cited 15 January 2024]. Available from: [https://www.aph.gov.au/Parliamentary\\_Business/Committees/House/Health\\_Aged\\_Care\\_and\\_Sport/Allergiesandanaphylaxis/Report/section?id=committees%2Freportrep%2F024422%2F72559](https://www.aph.gov.au/Parliamentary_Business/Committees/House/Health_Aged_Care_and_Sport/Allergiesandanaphylaxis/Report/section?id=committees%2Freportrep%2F024422%2F72559) accessed 2024 15 January.

8. Bosnic-Anticevich S, Smith P, Abramson M, et al. Impact of allergic rhinitis on the day-to-day lives of children: insights from an Australian cross-sectional study. *BMJ open* 2020;10(11):e038870.

9. McDonald VM, Hiles SA, Jones KA, et al. Health-related quality of life burden in severe asthma. *Medical Journal of Australia* 2018;209(S2):S28-S33.

10. Gupta R, Holdford D, Bilaver L, et al. The economic impact of childhood food allergy in the United States. *JAMA pediatrics* 2013;167(11):1026-31.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

11. Hua X, Dalziel K, Brettig T, et al. Out-of-hospital health care costs of childhood food allergy in Australia: A population-based longitudinal study. *Pediatric Allergy and Immunology* 2022;33(11):e13883.
12. Jiang J, Warren CM, Brewer A, et al. Racial, Ethnic, and Socioeconomic Differences in Food Allergies in the US. *JAMA Network Open* 2023;6(6):e2318162-e62.
13. Suaini NH, Loo EXL, Peters RL, et al. Children of Asian ethnicity in Australia have higher risk of food allergy and early-onset eczema than those in Singapore. *Allergy* 2021;76(10):3171-82.
14. Panjari M, Koplin J, Dharmage S, et al. Nut allergy prevalence and differences between Asian-born children and Australian-born children of Asian descent: a state-wide survey of children at primary school entry in Victoria, Australia. *Clinical & Experimental Allergy* 2016;46(4):602-09.
15. Jafri S, Janzen J, Kim R, et al. Burden of allergic disease in racial and ethnic structurally oppressed communities within Canada and the United States: a scoping review. *The Journal of Allergy and Clinical Immunology: In Practice* 2022;10(11):2995-3001.
16. Ahmed A, Hakim A, Becker A. Evaluation of eczema, asthma, allergic rhinitis and allergies among the grade-1 children of Iqaluit. *Allergy, Asthma & Clinical Immunology* 2018;14:1-14.
17. Courtney A, Lopez DJ, Lowe AJ, et al. Burden of disease and unmet needs in the diagnosis and management of atopic dermatitis in diverse skin types in Australia. *Journal of Clinical Medicine* 2023;12(11):3812.
18. AIHW. Profile of First Nations people [cited 17 January 2024]. Available from: <https://www.aihw.gov.au/reports/australias-welfare/profile-of-indigenous-australians> accessed 2024 17 January.
19. Australian Government Department of Health and Aged care AaTSIh. Status and determinants of Aboriginal and Torres Strait Islander health [cited 17 January 2024]. Available from: <https://www.health.gov.au/topics/aboriginal-and-torres-strait-islander-health/status-and-determinants> accessed 2024 17 January.

1  
2  
3 390 20. Stephens C, Nettleton C, Porter J, et al. Indigenous peoples' health—why are they behind  
4  
5 391 everyone, everywhere? *The Lancet* 2005;366(9479):10-13.  
6  
7 392 21. ABS. National Aboriginal and Torres Strait Islander Health Survey: Statistics about long-term health  
8  
9 conditions, disability, lifestyle factors, physical harm and use of health services, 2018-19 [cited  
10 393 18 January 2024]. Available from: [https://www.abs.gov.au/statistics/people/aboriginal-and-](https://www.abs.gov.au/statistics/people/aboriginal-and-torres-strait-islander-peoples/national-aboriginal-and-torres-strait-islander-health-survey/latest-release)  
11  
12 394 [torres-strait-islander-peoples/national-aboriginal-and-torres-strait-islander-health-](https://www.abs.gov.au/statistics/people/aboriginal-and-torres-strait-islander-peoples/national-aboriginal-and-torres-strait-islander-health-survey/latest-release)  
13  
14 395 [survey/latest-release](https://www.abs.gov.au/statistics/people/aboriginal-and-torres-strait-islander-peoples/national-aboriginal-and-torres-strait-islander-health-survey/latest-release) accessed 2024 18 January.  
15  
16 396  
17  
18 397 22. AIHW. First Nations people with asthma [cited 18 January 2024]. Available from:  
19  
20 [https://www.aihw.gov.au/reports/chronic-respiratory-conditions/first-nations-people-with-](https://www.aihw.gov.au/reports/chronic-respiratory-conditions/first-nations-people-with-asthma)  
21 398 [asthma](https://www.aihw.gov.au/reports/chronic-respiratory-conditions/first-nations-people-with-asthma).  
22  
23 399  
24  
25 400 23. Al-Yaman F. The Australian Burden of Disease Study: impact and causes of illness and death in  
26  
27 Aboriginal and Torres Strait Islander people, 2011. *Public Health Research & Practice*  
28 401 2017;27(4)  
29  
30 402  
31  
32 403 24. Botha M, Basera W, Facey-Thomas HE, et al. Rural and urban food allergy prevalence from the  
33  
34 South African Food Allergy (SAFFA) study. *Journal of Allergy and Clinical Immunology*  
35 404 2019;143(2):662-68. e2.  
36  
37 405  
38  
39 406 25. Allen KJ, Koplin JJ. What can urban/rural differences in food allergy prevalence tell us about the  
40  
41 drivers of food allergy? *Journal of Allergy and Clinical Immunology* 2019;143(2):554-56.  
42  
43 408 26. Osborne NJ, Ukoumunne OC, Wake M, et al. Prevalence of eczema and food allergy is associated  
44  
45 with latitude in Australia. *Journal of allergy and clinical immunology* 2012;129(3):865-67.  
46 409  
47  
48 410 27. Khan A, Green K, Smoll N, et al. Roles, experiences and perspectives of the stakeholders of “10,000  
49  
50 Lives” smoking cessation initiative in Central Queensland: Findings from an online survey  
51 411 during COVID-19 situation. *Health Promotion Journal of Australia* 2022;33:316-26.  
52 412  
53  
54 413 28. Australian Bureau of Statistics. Digital boundary files; Australian Statistical Geography Standard  
55  
56 (ASGS) Edition 3. Reference period July 2021 - June 2026. [Available from:  
57 414 <https://www.abs.gov.au/statistics/standards/australian-statistical-geography-standard-asgs->  
58 415  
59  
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignment Supérieur (ABES).

- 416 [edition-3/jul2021-jun2026/access-and-downloads/digital-boundary-files](#) accessed 2024 31  
417 May.
- 418 29. Queensland Government. Central Queensland region [cited 23 January 2024]. Available from:  
419 [https://teach.qld.gov.au/teach-in-queensland-state-schools/our-schools/central-](https://teach.qld.gov.au/teach-in-queensland-state-schools/our-schools/central-queensland-region)  
420 [queensland-region](https://teach.qld.gov.au/teach-in-queensland-state-schools/our-schools/central-queensland-region) accessed 2024 23 January.
- 421 30. Queensland Government. Central Queensland Hospital and Health Service: Queensland Health;  
422 2016 [Available from: <https://www.health.qld.gov.au/cq> accessed 26/01/2019 2019.
- 423 31. Australian Government, Department of Health and Aged care. Health Workforce Locator [cited 08  
424 March 2024]. Available from: [https://www.health.gov.au/resources/apps-and-tools/health-](https://www.health.gov.au/resources/apps-and-tools/health-workforce-locator/app)  
425 [workforce-locator/app](https://www.health.gov.au/resources/apps-and-tools/health-workforce-locator/app) accessed 2024 08 March.
- 426 32. Australian Bureau of Statistics. Central Queensland: Australian Bureau of Statistics; 2022 [Available  
427 from: <https://www.abs.gov.au/census/find-census-data/quickstats/2021/3082023>.
- 428 33. Romanet-Manent S, Charpin D, Magnan A, et al. Allergic vs nonallergic asthma: what makes the  
429 difference? *Allergy* 2002;57(7):607-13.
- 430 34. Johansson S, Hourihane JB, Bousquet J, et al. A revised nomenclature for allergy: an EAACI position  
431 statement from the EAACI nomenclature task force. *Allergy* 2001;56(9):813-24.
- 432 35. Queensland Health. Terminology Guide: for the use of 'First Nations' and 'Aboriginal' and 'Torres  
433 Strait Islander' peoples references [cited 09 April 2024]. Available from:  
434 [https://www.health.qld.gov.au/\\_data/assets/pdf\\_file/0031/147919/terminology.pdf](https://www.health.qld.gov.au/_data/assets/pdf_file/0031/147919/terminology.pdf)  
435 accessed 2024 09 April.
- 436 36. Australian Bureau of Statistics. Central Queensland: 2021 Census All persons QuickStats [cited 30  
437 January 2024]. Available from: [https://www.abs.gov.au/census/find-census-](https://www.abs.gov.au/census/find-census-data/quickstats/2021/308)  
438 [data/quickstats/2021/308](https://www.abs.gov.au/census/find-census-data/quickstats/2021/308) accessed 2024 30 January.
- 439 37. Valery PC, Masters IB, Chang A. Asthma is not prevalent in Aboriginal and Torres Strait Islander  
440 children: a myth. *Journal of Paediatrics and Child Health* 2002;38(1):105-06.

1  
2  
3 441 38. AIHW. Data update: Short-term health impacts of the 2019–20 Australian bushfires [cited 16  
4  
5 442 January 2024]. Available from: [https://www.aihw.gov.au/reports/environment-and-](https://www.aihw.gov.au/reports/environment-and-health/data-update-health-impacts-2019-20-bushfires/contents/about)  
6  
7 443 [health/data-update-health-impacts-2019-20-bushfires/contents/about](https://www.aihw.gov.au/reports/environment-and-health/data-update-health-impacts-2019-20-bushfires/contents/about) accessed 2024 16  
8  
9 444 January  
10  
11  
12 445 39. Liu JC, Pereira G, Uhl SA, et al. A systematic review of the physical health impacts from non-  
13  
14 446 occupational exposure to wildfire smoke. *Environmental research* 2015;136:120-32.  
15  
16 447 40. Asthma Australia. Bushfire Smoke Impacts Survey 2019-2020- Bushfire Smoke: Are You Coping?  
17  
18 448 2020  
19  
20 449 41. Adegbija O, Walker J, Smoll N, et al. Notifiable diseases after implementation of COVID-19 public  
21  
22 450 health prevention measures in Central Queensland, Australia. *Communicable diseases*  
23  
24 451 *intelligence (2017: Online)* 2021  
25  
26 452 42. Papadopoulos NG, Christodoulou I, Rohde G, et al. Viruses and bacteria in acute asthma  
27  
28 453 exacerbations—A GA2LEN-DARE\* systematic review. *Allergy* 2011;66(4):458-68.  
29  
30 454 43. AIHW. Chronic respiratory conditions: Asthma [cited 16 January 2024]. Available from:  
31  
32 455 <https://www.aihw.gov.au/reports/chronic-respiratory-conditions/asthma> accessed 2024 16  
33  
34 456 January.  
35  
36 457 44. Brew B, Gibberd A, Marks GB, et al. Identifying preventable risk factors for hospitalised asthma in  
37  
38 458 young Aboriginal children: a whole-population cohort study. *Thorax* 2021;76(6):539-46.  
39  
40 459 45. AIHW. Australian Burden of Disease Study: Impact and causes of illness and death in Aboriginal  
41  
42 460 and Torres Strait Islander people 2018. *Canberra: AIHW* 2022  
43  
44 461 46. Brock C, McGuane J. Determinants of asthma in Indigenous Australians: insights from  
45  
46 462 epidemiology. *Austr Indigenous Health Bulletin* 2018;18(2):12-20.  
47  
48 463 47. Haggett MG, Tait CP. Five years of dermatological disease requiring specialist care in the Kimberley  
49  
50 464 region of Western Australia. *Australasian Journal of Dermatology* 2021;62(2):157-61.  
51  
52 465 48. Lai-Kwon J, Weiland TJ, Chong AH, et al. Which dermatological conditions present to an emergency  
53  
54 466 department in Australia? *Emergency Medicine International* 2014;2014  
55  
56  
57  
58  
59  
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Enseignement Supérieur (ABES)



49. Silverberg JI. Comorbidities and the impact of atopic dermatitis. *Annals of Allergy, Asthma & Immunology* 2019;123(2):144-51.
50. Alexander H, Paller A, Traidl-Hoffmann C, et al. The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group. *British Journal of Dermatology* 2020;182(6):1331-42.
51. Sugarman JL, Hersh AL, Okamura T, et al. A retrospective review of streptococcal infections in pediatric atopic dermatitis. *Pediatric dermatology* 2011;28(3):230-34.
52. Brook I, Frazier EH, Yeager JK. Microbiology of infected atopic dermatitis. *International journal of dermatology* 1996;35(11):791-93.
53. Benenson S, Zimhony O, Dahan D, et al. Atopic dermatitis—a risk factor for invasive *Staphylococcus aureus* infections: two cases and review. *The American Journal of Medicine* 2005;118(9):1048-51.
54. Patel D, Jahnke MN. Serious complications from *Staphylococcal aureus* in atopic dermatitis. *Pediatric dermatology* 2015;32(6):792-96.
55. Serrano L, Patel KR, Silverberg JI. Association between atopic dermatitis and extracutaneous bacterial and mycobacterial infections: a systematic review and meta-analysis. *Journal of the American Academy of Dermatology* 2019;80(4):904-12.
56. Valery PC, Wenitong M, Clements V, et al. Skin infections among Indigenous Australians in an urban setting in far North Queensland. *Epidemiology & Infection* 2008;136(8):1103-08.
57. Mullins RJ, Dear KB, Tang ML. Time trends in Australian hospital anaphylaxis admissions in 1998-1999 to 2011-2012. *Journal of Allergy and Clinical Immunology* 2015;136(2):367-75.
58. Stiles SL, Sanfilippo FM, KS RL, et al. Contemporary trends in anaphylaxis burden and healthcare utilisation in Western Australia: A linked data study. *World Allergy Organization Journal* 2023;16(9):100818.



1  
2  
3 491 59. Drewett GP, Encena J, Gregory J, et al. Anaphylaxis in Victoria: presentations to emergency  
4  
5 492 departments, with a focus on drug-and antimicrobial-related cases. *Medical Journal of*  
6  
7 493 *Australia* 2022;216(10):520-24.  
8  
9  
10 494 60. Losappio L, Heffler E, Bussolino C, et al. Acute urticaria presenting in the emergency room of a  
11  
12 495 general hospital. *European Journal of Internal Medicine* 2014;25(2):147-50.  
13  
14 496 61. Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international  
15  
16 497 EAACI/GA<sup>2</sup>LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis,  
17  
18 498 and management of urticaria. *Allergy* 2022;77(3):734-66.  
19  
20  
21 499 62. Jadhav R, Alcalá E, Sirota S, et al. Risk factors for acute urticaria in Central California. *International*  
22  
23 500 *Journal of Environmental Research and Public Health* 2021;18(7):3728.  
24  
25 501 63. Thomsen SF, Van der Sluis S, Kyvik KO, et al. Urticaria in monozygotic and dizygotic twins. *Journal*  
26  
27 502 *of allergy* 2012;2012  
28  
29 503 64. Hu Y, Chen Y, Liu S, et al. Breastfeeding duration modified the effects of neonatal and familial risk  
30  
31 504 factors on childhood asthma and allergy: a population-based study. *Respiratory research*  
32  
33 505 2021;22(1):1-11.  
34  
35 506 65. Kolkhir P, Giménez-Arnau AM, Kulthanan K, et al. Urticaria. *Nature Reviews Disease Primers*  
36  
37 507 2022;8(1):61.  
38  
39 508 66. Gabrielle P, Hashim MJ, Shaughnessy C, et al. Global epidemiology of urticaria: increasing burden  
40  
41 509 among children, females and low-income regions. *Acta Dermato-Venereologica* 2021;101(4)  
42  
43 510 67. Australian Indigenous HealthInfoNet. Summary of respiratory diseases among Aboriginal and  
44  
45 511 Torres Strait Islander children *Perth, WA Australian Indigenous HealthInfoNet*  
46  
47 512 *healthinfoNetecueduau/respiratory* 2022  
48  
49 513 68. Perry TT, Grant TL, Dantzer JA, et al. Impact of socioeconomic factors on allergic diseases. *Journal*  
50  
51 514 *of Allergy and Clinical Immunology* 2023  
52  
53  
54  
55  
56  
57 515  
58  
59  
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Enseignement Supérieur (ABES)

**Table 1.** Background characteristics of patients presenting with asthma and allergic diseases compared to individuals presenting to ED for other reasons (N=813112)

Variable	Asthma and allergic disease-related ED presentations		P value
	No	Yes	
Indigenous status (n=812995)			
First Nations Australians	107099 (98.4)	1755 (1.6)	0.569
Australians of other descent /Not Stated	692623 (98.4)	11518 (1.6)	
Sex			
Female	397513 (98.2)	7395 (1.8)	< 0.001
Male and intersex	402325 (98.6)	5879 (1.4)	
Age group (Year, n=813111)			
≤4	78484 (97.5)	2018 (2.5)	< 0.001
5-14	87248 (97.2)	2540 (2.8)	
15-29	180778 (98.4)	2905 (1.6)	
30-44	148,015 (98.5)	2285 (1.5)	
45-59	129214 (98.4)	2051 (1.6)	
60+	176,098 (99.2)	1475 (0.8)	
Hospital			
Baralaba	1234(98.9)	14(1.1)	<0.001
Biloela	41009(98.0)	853(2.0)	
Blackwater	25048 (98.1)	474 (1.9)	
Emerald	83599(98.6)	1216 (1.4)	
Gladstone	203136(98.2)	3618(1.8)	
Mount Morgan	15972(98.1)	301(1.9)	
Moura	12457(98.1)	241(1.9)	
Rockhampton	298827(98.6)	4311(1.4)	
Springsure	7983(98.2)	144(1.8)	
Theodore	1414(98.7)	19(1.3)	
Woorabinda	12894(98.2)	239(1.8)	
Yeppoon	96265(98.1)	1844(1.9)	

ED= Emergency Department

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 2.** Incidence rate of asthma and allergic diseases from 2018 to 2023.

Asthma and allergic diseases	Asthma and specific type of allergy (per 10000 person-year with 95% CI)		
	First Nations Australians	Australians of other descent	Overall
Asthma*	87.8 (82.0, 93.8)	40.2 (39.0, 41.3)	40.5 (39.4, 41.5)
Unspecified allergy*	55.3 (50.8, 60.2)	36.0 (34.9, 37.1)	34.6 (33.6, 35.6)
Atopic/allergic contact dermatitis*	17.1 (14.6, 19.9)	10.6 (10.0, 11.2)	10.3 (9.7, 10.8)
Anaphylaxis and anaphylactic shock	7.2 (5.6, 9.1)	6.2 (5.7, 6.6)	5.8 (5.4, 6.2)
Allergic urticaria*	4.0 (2.9, 5.5)	2.3 (2.1, 2.6)	2.3 (2.0, 2.5)
Allergic conjunctivitis*	3.6 (2.5, 5.0)	2.4 (2.1, 2.7)	2.3 (2.1, 2.6)
Allergic rhinitis*	1.9 (1.2, 3.0)	0.7 (0.6, 0.9)	0.8 (0.6, 0.9)
Allergic purpura	0.5 (0.2, 1.2)	0.5 (0.4, 0.7)	0.5 (0.4,0.6)
Overall allergic diseases*, **	89.7 (83.9, 95.8)	58.8 (57.4, 60.2)	56.4 (55.2, 57.7)


\*P value < 0.05 when comparing the incidence rate per person-year between First Nations Australians and Australians of other descent, \*\*Overall allergic diseases encompass all specific allergic diseases, including unspecified allergy, atopic/allergic contact dermatitis, anaphylaxis, and anaphylactic shock, allergic urticaria, allergic conjunctivitis, allergic rhinitis, and allergic purpura but not asthma

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

**Table 3.** Incidence of asthma and allergic disease-related ED presentations (per 10,000 person-years) from 2018 to 2023


Year	Asthma and allergic disease-related ED presentations							
	Sex		Age (Year)					
	Female	Male and intersex	0-4	5-14	15-29	30-44	45-59	60+
2018	101.2	78.2	281.6	111.9	99.0	75.0	64.5	47.9
2019	116.7	89.4	262.6	147.8	119.0	77.5	82.5	55.4
2020	105.4	80.7	208.9	105.0	108.9	98.3	80.5	44.7
2021	123.6	97.2	240.7	134.2	138.5	100.1	95.3	57.0
2022	111.9	86.9	222.3	134.2	135.6	84.2	74.5	46.3
2023	96.6	76.9	208.2	133.0	97.4	76.6	60.9	44.5
IRR (95% CI)	0.99 (0.95, 1.04)	1.001 (0.951, 1.053)	0.94 (0.91, 0.97)	1.02 (0.97, 1.06)	1.02 (0.97, 1.06)	1.01 (0.96, 1.06)	0.98 (0.93, 1.04)	0.98 (0.91, 1.05)
P value	0.824	0.974	<0.001	0.320	0.432	0.700	0.710	0.587

ED= Emergency Department, IRR= Incidence rate ratio, CI= Confidence interval



**Figure 1.** Incidence of both asthma and allergic disease-related Emergency Department presentations in Central Queensland between 2018 and 2023  
ED= Emergency Department

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignment Supérieur (ABES).



**Figure 2.** Separate incidence of asthma and allergic disease-related Emergency Department presentations in Central Queensland between 2018 and 2023  
ED= Emergency Department

**Supplemental Table 1.** ICD-10-AM codes related to allergic conditions.


Condition	ICD-10-AM Code
Allergy, unspecified	T78.4, Z91.0
Allergic atopic dermatitis	L20, L20.8, L20.9
Allergic contact dermatitis	L23, L23.0-L23.9
Allergic conjunctivitis	H10.1, H10.2, H10.3, H10.4,
Allergic gastroenteritis	K52.2
Allergic purpura	D69.0
Allergic rhinitis	J30, J30.1, J30.2, J30.3, J30.4, J30.5
Allergic urticaria	L50.0, L50.8
Anaphylaxis	T78.0, T78.1, T78.2, T80.5, T88.6
Asthma	J45.0, J45.8, J45.9, J46
Food allergy	Y37.0-Y37.9, Y37.2, Y37.20, Y37.21, Y37.22, Y37.23, Y37.29, Y37.3, Y37.30, Y37.31, Y37.32, Y37.39, Y37.4, Y37.5

**Supplemental Table 2.** Emergency Department presentations at Public Hospitals in Central Queensland, 1 January 2018 to 30 November 2023 (N=813, 122)

Hospital	Year Frequency (%)						Total
	2018	2019	2020	2021	2022	2023	
Baralaba	X	X	X	237 (19.0)	547 (43.8)	464 (37.2)	1248 (100.0)
Biloela	6549 (15.6)	6394 (15.3)	7312 (17.5)	7268 (17.4)	7294 (17.4)	7045 (16.8)	41862 (100.0)
Blackwater	1207 (4.7)	5184 (20.3)	4453 (17.5)	4651 (18.2)	4752 (18.6)	5275 (20.7)	25522 (100.0)
Emerald	12320 (14.5)	13129 (15.5)	13110 (15.5)	16036 (18.9)	15639 (18.4)	1458 (17.2)	84815 (100.0)
Gladstone	31065 (15.0)	34340 (16.6)	36627 (17.7)	36349 (17.6)	36209 (17.5)	32164 (15.6)	206754 (100.0)
Mount Morgan	805 (4.9)	2925 (18.0)	2820 (17.3)	3280 (20.2)	3448 (21.2)	2995 (18.4)	16273 (100.0)
Moura	481 (3.8)	2158 (17.0)	2410 (19.0)	3118 (24.5)	2603 (20.5)	1928 (15.2)	12698 (100.0)
Rockhampton	47270 (15.5)	50522 (16.7)	49869 (16.5)	55777 (18.4)	52708 (17.4)	46992 (15.5)	303138 (100.0)
Springsure	337 (4.1)	1565 (19.3)	1697 (20.9)	1644 (20.2)	1535 (18.9)	1349 (16.6)	8127 (100.0)
Theodore	X	X	X	290 (20.2)	586 (40.9)	557 (38.9)	1433 (100.0)
Woorabinda	380 (2.9)	2107 (16.0)	2497 (19.0)	2476 (18.9)	2903 (22.1)	2770 (21.1)	13133 (100.0)
Yeppoon	14540 (14.8)	15017 (15.3)	15500 (15.8)	19797 (20.2)	17577 (17.9)	15678 (16.0)	98109 (100.0)
Total	114954 (14.1)	133341 (16.4)	136295 (16.8)	150923 (18.6)	145801 (17.9)	131798 (16.2)	813112 (100.0)

X= ED services were not available.





**Supplemental Figure 1.** Locator map of the study area.

**Source:** The map was developed using the digital boundary files from the Australian Bureau of Statistics.

# BMJ Open

## Emergency Department presentations related to asthma and allergic diseases in Central Queensland, Australia: a comparative analysis between First Nations Australians and Australians of other descents

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2024-091482.R1
Article Type:	Original research
Date Submitted by the Author:	15-Jan-2025
Complete List of Authors:	Shifti, Desalegn Markos; The University of Queensland, Child Health Research Centre, ; Murdoch Children's Research Institute, Centre for Food and Allergy Research (CFAR) Al Imam, Mahmudul Hassan ; Central Queensland Hospital and Health Service, Central Queensland Public Health Unit Maresco-Pennisi, Diane; The University of Queensland, Centre for Clinical Research Whitcombe, Renarta; Central Queensland Hospital and Health Service, Central Queensland Public Health Unit, Sly, P.D.; The University of Queensland, Children's Health and Environment Program, Child Health Research Centre Munns, Craig; The University of Queensland, Child Health Research Centre; The University of Queensland, Faculty of Medicine Peters, Rachel ; Murdoch Children's Research Institute; University of Melbourne, Department of Paediatrics Khandaker, Gulam; The University of Queensland, Child Health Research Centre; Central Queensland Hospital and Health Service, Central Queensland Public Health Unit Koplin, Jennifer J; The University of Queensland, Child Health Research Centre; Murdoch Children's Research Institute, Centre for Food and Allergy Research (CFAR)
<b>Primary Subject Heading</b>:	Epidemiology
Secondary Subject Heading:	Emergency medicine, Epidemiology, Health services research, Public health, Immunology (including allergy)
Keywords:	Chronic Disease, EPIDEMIOLOGIC STUDIES, EPIDEMIOLOGY, Prevalence, Asthma < THORACIC MEDICINE, Emergency Service, Hospital

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Emergency Department presentations related to asthma and allergic diseases in Central Queensland, Australia: a comparative analysis between First Nations Australians and Australians of other descents**

**Authors:** Desalegn Markos Shifti<sup>a,b</sup>, PhD, Mahmudul Hassan Al Imam<sup>c</sup>, PhD, Diane Maresco-Pennisi<sup>d</sup>, PhD, Renarta Whitcombe<sup>e</sup>, GDip, Peter D Sly<sup>e</sup>, MD, DSc, Craig F Munns<sup>a,f,g</sup>, PhD, Rachel L Peters<sup>h,i</sup>, PhD, Gulam Khandaker<sup>a,c</sup>, PhD, Jennifer J Koplin<sup>a,b,h</sup>, PhD

**Affiliations:**

<sup>a</sup>Child Health Research Centre, The University of Queensland, South Brisbane, QLD, Australia

<sup>b</sup>Centre for Food and Allergy Research (CFAR), Murdoch Children’s Research Institute, Parkville, VIC, Australia

<sup>c</sup>Central Queensland Public Health Unit, Central Queensland Hospital and Health Service, Rockhampton, QLD, Australia

<sup>d</sup>Centre for Clinical Research, The University of Queensland, Brisbane, QLD, Australia

<sup>e</sup>Children’s Health and Environment Program, Child Health Research Centre, The University of Queensland, South Brisbane, Australia

<sup>f</sup>Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia

<sup>g</sup>Department of Endocrinology and Diabetes, Queensland Children’s Hospital, Brisbane, QLD, Australia

<sup>h</sup>Murdoch Children’s Research Institute, Parkville, VIC, Australia

<sup>i</sup>Department of Paediatrics, University of Melbourne, Parkville, Australia

**Email address:**

Desalegn Markos Shifti: [d.shifti@uq.edu.au](mailto:d.shifti@uq.edu.au)

Mahmudul Hassan Al Imam: [mahmudul.alimam@health.qld.gov.au](mailto:mahmudul.alimam@health.qld.gov.au)

Diane Maresco-Pennisi: [d.marescopennisi@uq.edu.au](mailto:d.marescopennisi@uq.edu.au)

Renarta Whitcombe: [Renarta.Whitcombe@health.qld.gov.au](mailto:Renarta.Whitcombe@health.qld.gov.au)

Peter D Sly: [p.sly@uq.edu.au](mailto:p.sly@uq.edu.au)

Craig F Munns: [c.munns@uq.edu.au](mailto:c.munns@uq.edu.au)

Rachel L Peters: [rachel.peters@mcri.edu.au](mailto:rachel.peters@mcri.edu.au)

Gulam Khandaker: [gulam.khandaker@health.qld.gov.au](mailto:gulam.khandaker@health.qld.gov.au)

Jennifer J Koplin: [j.koplin@uq.edu.au](mailto:j.koplin@uq.edu.au)

**Corresponding author:** Desalegn Markos Shifti. Email: [d.shifti@uq.edu.au](mailto:d.shifti@uq.edu.au); Level 6, 62 Graham Street, South Brisbane, QLD 4101, Australia.

## Abstract

**Objective:** To examine the overall incidence rate and trends in Emergency Department (ED) presentations related to asthma and allergic diseases in regional Australia with a particular focus on First Nations Australians.

**Design:** A retrospective analysis of data from the Emergency Department Information System.

**Setting:** This study used data from 12 public hospitals in Central Queensland, Australia, a region encompassing regional, rural, and remote outback areas.

**Participants:** A total of 813,112 ED presentations between 2018 and 2023.

**Outcome measure:** Asthma and allergic diseases were identified using the International Classification of Diseases-Tenth Revision-Australian Modification (ICD-10-AM) codes.

**Results:** There were 13,273 asthma and allergic disease-related ED presentations, with an overall prevalence of 1.6% (95% confidence interval (CI): 1.6, 1.7). There was a significantly higher incidence rate of asthma and allergic disease-related ED presentations among First Nations Australians at 177.5 per 10,000 person-years (95% CI: 169.3, 186.0), compared to 98.9 per 10,000 person-years (95% CI: 97.2, 100.8) among Australians of other descents. The incidence rates, with corresponding 95% CI, of the four most common cases among First Nations Australians and Australians of other descents, respectively, were as follows: asthma (87.8 (82.0, 93.8) and 40.2 (39.0, 41.3)), unspecified allergy (55.3 (50.8, 60.2) and 36.0 (34.9, 37.1)), atopic/allergic contact dermatitis (17.1 (14.6, 19.9) and 10.6 (10.0, 11.2)), and anaphylaxis (7.2 (5.6, 9.1) and 6.2 (5.7, 6.6)).

**Conclusion:** Our findings highlight a significantly higher rate of asthma and allergic disease-related ED presentations among First Nations Australians compared to Australians of other descents. This underscores the urgent need for targeted healthcare interventions integrating culturally appropriate approaches, alongside additional research to understand causality.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744

745

746

747

748

749

750

751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

781

782

783

784

785

786

787

788

789

790

791

792

793

794

795

796

797

798

799

800

801

802

803

804

805

806

807

808

809

810

811

812

813

814

815

816

817

818

819

820

821

822

823

824

825

826

827

828

829

830

831

832

833

834

835

836

837

838

839

840

841

842

843

844

845

846

847

848

849

850

851

852

853

854

855

856

857

858

859

860

861

862

863

864

865

866

867

868

869

870

871

872

873

874

875

876

877

878

879

880

881

882

883

884

885

886

887

888

889

890

891

892

893

894

895

896

897

898

899

900

901

902

903

904

905

906

907

908

909

910

911

912

913

914

915

916

917

918

919

920

921

922

923

924

925

926

927

928

929

930

931

932

933

934

935

936

937

938

939

940

941

942

943

944

945

946

947

948

949

950

951

952

953

954

955

956

957

958

959

960

961

962

963

964

965

966

967

968

969

970

971

972

973

974

975

976

977

978

979

980

981

982

983

984

985

986

987

988

989

990

991

992

993

994

995

996

997

998

999

1000

1001

1002

1003

1004

1005

1006

1007

1008

1009

1010

1011

1012

1013

1014

1015

1016

1017

1018

1019

1020

1021

1022

1023

1024

1025

1026

1027

1028

1029

1030

1031

1032

1033

1034

1035

1036

1037

1038

1039

1040

1041

1042

1043

1044

1045

1046

1047

1048

1049

1050

1051

1052

1053

1054

1055

1056

1057

1058

1059

1060

1061

1062

1063

1064

1065

1066

1067

1068

1069

1070

1071

1072

1073

1074

1075

1076

1077

1078

1079

1080

1081

1082

1083

1084

1085

1086

1087

1088

1089

1090

1091

1092

1093

1094

1095

1096

1097

1098

1099

1100

1101

1102

1103

1104

1105

1106

1107

1108

1109

1110

1111

1112

1113

1114

1115

1116

1117

1118

1119

1120

1121

1122

1123

1124

1125

1126

1127

1128

1129

1130

1131

1132

1133

1134

1135

1136

1137

1138

1139

1140

1141

1142

1143

1144

1145

1146

1147

1148

1149

1150

1151

1152

1153

1154

1155

1156

1157

1158

1159

1160

1161

1162

1163

1164

1165

1166

1167

1168

1169

1170

1171

1172

1173

1174

1175

1176

1177

1178

1179

1180

1181

1182

1183

1184

1185

1186

1187

1188

1189

1190

1191

1192

1193

1194

1195

1196

1197

1198

1199

1200

1201

1202

1203

1204

1205

1206

1207

1208

1209

1210

1211

1212

1213

1214

1215

1216

1217

1218

1219

1220

1221

1222

1223

1224

1225

1226

1227

1228

1229

1230

1231

1232

1233

1234

1235

1236

1237

1238

1239

1240

1241

1242

1243

1244

1245

1246

1247

1248

1249

1250

1251

1252

1253

1254

1255

1256

1257

1258

1259

1260

1261

1262

1263

1264

1265

1266

1267

1268

1269

1270

1271

1272

1273

1274

1275

1276

1277

1278

1279

1280

1281

1282

1283

1284

1285

1286

1287

1288

1289

1290

1291

1292

1293

1294

1295

1296

1297

1298

1299

1300

1301

1302

1303

1304

1305

1306

1307

1308

1309

1310

1311

1312

1313

1314

1315

1316

1317

1318

1319

1320

1321

1322

1323

1324

1325

1326

1327

1328

1329

1330

1331

1332

1333

1334

1335

1336

1337

1338

1339

1340

1341

1342

1343

1344

1345

1346

1347

1348

1349

1350

1351

1352

1353

1354

1355

1356

1357

1358

1359

1360

1361

1362

1363

1364

1365

1366

1367

1368

1369

1370

1371

1372

1373

1374

1375

1376

1377

1378

1379

1380

1381

1382

1383

1384

1385

1386

1387

1388

1389

1390

1391

1392

1393

1394

1395

1396

1397

1398

1399

1400

1401

1402

1403

1404

1405

1406

1407

1408

1409

1410

1411

1412

1413

1414

1415

1416

1417

1418

1419

1420

1421

1422

1423

1424

1425

1426

1427

1428

1429

1430

1431

1432

1433

1434

1435

1436

1437

1438

1439

1440

1441

1442

1443

1444

1445

1446

1447

1448

1449

1450

1451

1452

1453

1454

1455

1456

1457

1458

1459

1460

1461

1462

1463

1464

1465

1466

1467

1468

1469

1470

1471

1472

1473

1474

1475

1476

1477

1478

1479

1480

1481

1482

1483

1484

1485

1486

1487

## Strengths and limitations of the study

- The study uses the most recent, large data set including First Nations Australians and Australians of other descents and all age groups from a study setting encompassing regional, rural, and remote outback areas.
- The reporting of ED presentations related to asthma and allergic disease relies on the ICD codes entered by physicians at the time of presentation.
- Our study specifically focused on asthma and allergic disease-related ED presentations and did not encompass all instances of acute asthma and allergic diseases in the general population which may visit health facilities in routes other than ED.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

76    **Introduction**

77    Chronic diseases including asthma and allergy, are a leading cause of premature death and morbidity

78    globally<sup>1 2</sup> and constitute a growing public health concern.<sup>3-5</sup> It is estimated that by 2050, 50% of the

79    world's population will be affected by allergies.<sup>1 6</sup> In Australia, often labelled as the ‘allergy capital of

80    the world’,<sup>7</sup> allergy is currently estimated to affect 4.1 million people and is anticipated to undergo a

81    70% surge, with affected individuals projected to reach 7.7 million (26.1%) by 2050.<sup>3</sup>

82    Allergic diseases exert considerable economic and social impact and negatively impact individuals’ and

83    families’ day-to-day living as well as quality of life.<sup>8 9</sup> The overall economic cost of food allergy alone

84    in the United States was estimated to be USD 24.8 billion annually or USD 4184 per child.<sup>10</sup> The total

85    Medicare cost for out-of-hospital services related to food allergy in children aged 1 to 4 years in

86    Melbourne, Australia alone was estimated at AUD 26.1 million annually.<sup>11</sup>

87    There are clear racial, ethnic, and socioeconomic disparities in allergic diseases worldwide.<sup>12-14</sup> Studies

88    conducted on the burden of allergic disease in racially and ethnically structurally oppressed

89    communities in Canada and the United States (US) showed an increased burden of allergic and atopic

90    diseases (eczema, allergic rhinitis and asthma) among the Indigenous peoples of Canada.<sup>15 16</sup> In

91    Australia, the burden of disease in general is 2.3 times higher among First Nations Australians,<sup>17</sup> and

92    health outcomes are poorer when compared to Australians of other descents.<sup>18</sup> Asthma was the

93    second most commonly reported long-term condition (16.6%) affecting First Nations Australians.<sup>19 20</sup>

94    After adjusting for age difference, First Nations Australians were 1.6 times more likely to report having

95    asthma compared to Australians of other descent.<sup>21</sup> However, there has been little research into other

96    types of allergic disease in First Nations Australians.<sup>22</sup> In our study, the phrase ‘First Nations

97    Australians’ respectfully refers to the Aboriginal and Torres Strait Islander peoples in Australia.<sup>23</sup>

98    Existing evidence from other countries suggests that disparities in the prevalence of allergic diseases

99    exist between rural and urban areas. For example, a study conducted in South Africa reported a higher

100    prevalence of self-reported allergies and a higher prevalence of objectively measured food allergy in



urban areas compared to rural areas.<sup>24 25</sup> This underscores the importance of conducting region-specific studies to inform targeted interventions and healthcare strategies. There has been little research into allergic disease in regional and rural areas of Australia. The lack of comprehensive data in these areas hinders our understanding of the unique factors influencing allergies in regional settings, including distinct environmental exposures and lifestyle variations. Although some evidence<sup>26</sup> suggests that certain allergies, including food allergies and eczema, may be less common in Northern Australia based on self-report, region-specific further studies are required to inform targeted interventions and healthcare strategies.

The current study endeavours to fill some of the existing evidence gaps by examining incidence rate and trends of ED presentations related to asthma and allergic diseases, both collectively and individually, among both First Nations Australians and Australians of other descents in Central Queensland, which encompasses both regional and rural and remote areas, from 2018 to 2023. The focus on asthma and allergic disease-related ED presentations in our study is guided by several key considerations. First, ED data provide a relatively accessible and reliable means to investigate asthma and allergic diseases without extensive logistical requirements. Moreover, ED data capture the burden of severe and life-threatening cases that necessitate immediate medical attention, highlighting the acute impact of these conditions. Such data are critical for identifying gaps in preventive care, timely access to treatment, and community health resources, particularly in regional, rural and remote areas. Furthermore, the acute care dimensions of asthma and allergic diseases, especially among Indigenous people in regional, remote and rural, are often overlooked in the literature. By addressing these aspects, our study aims to fill these gaps and complement existing prevalence-focused research.

## Methods

### Study design and settings

We conducted a retrospective analysis of routinely collected data from the Emergency Department Information System (EDIS) of Public Hospitals in Central Queensland (CQ), a regional district of

1  
2  
3 126 Queensland, Australia, located in the central east region (the study area map can be found in online  
4  
5 127 Supplemental Figure 1).<sup>27</sup> The map was developed using the digital boundary files from the Australian  
6  
7 128 Bureau of Statistics.<sup>28</sup> CQ encompasses rural and remote outback towns.<sup>29</sup> This study targeted the  
8  
9  
10 129 service catchment area of Central Queensland Hospital and Health Service (CQHHS) and included all  
11  
12 130 patients presenting to the emergency department. CQHHS operates 12 public hospitals across various  
13  
14 131 regions. These include 1) Rockhampton, Mount Morgan, and Capricorn Coast, situated within Inner  
15  
16 132 Regional Australia, 2) Gladstone, Biloela, Emerald, Baralaba, Moura, Theodore, and Blackwater, which  
17  
18  
19 133 fall under Outer Regional Australia, and 3) Woorabinda and Springsure, located in Remote Australia.<sup>30</sup>  
20  
21 134 <sup>31</sup> CQHHS also provides Aboriginal and Torres Strait Islander Health, Maternity services, CQ Cancer  
22  
23 135 Care Services, Mental Health, Alcohol and Other Drugs Services, Oral Health and General Practitioner  
24  
25 136 referrals.<sup>30</sup> Data from the 2021 national census show that the CQ region was populated by 228,246  
26  
27  
28 137 people.<sup>32</sup> There were 59,070 families in CQ; the median age was 38 years and 64% of the population  
29  
30 138 was aged between 15–64 years.<sup>32</sup> Over seven per cent (7.2%) of the total population in CQ identify as  
31  
32 139 First Nations Australians.<sup>32</sup>

34  
35 140 **Participants**

36  
37  
38 141 Our analysis included all ED presentation data from the CQHHS catchment areas, spanning January  
39  
40 142 2018 to November 2023, regardless of age or sex.

41  
42  
43 143 **Variables**

44  
45  
46 144 We described the overall asthma and allergic disease-related ED presentations using covariates  
47  
48 145 available in the administrative data. These were self-reported Indigenous status (Aboriginal and/or  
49  
50 146 Torres Strait Islanders, which are categorised into First Nations Australians, and not-Indigenous and  
51  
52 147 not stated, which are categorised into Australians of other descents<sup>33</sup>), sex (female, male, and  
53  
54 148 intersex), age group in years ( $\leq 4$ , 5-14, 15-29, 30-44, 45-59, 60+), hospital (Baralaba, Biloela,  
55  
56 149 Blackwater, Emerald, Gladstone, Mount Morgan, Moura, Rockhampton, Springsure, Theodore,  
57  
58 150 Woorabinda, and Yeppoon) as indirect indicator of place of residence.

## 151 Data source and measurement

152 Data were retrieved in a one-time extraction from the Business Analysis Decision Support (BADs)  
153 portal, deidentified, replaced with unique codes, and securely stored. The extraction was conducted  
154 by an experienced and expert data custodian following the CQHHS data extraction protocol. ED  
155 presentations related to asthma and allergic diseases were identified using the International  
156 Classification of Diseases-Tenth Revision-Australian Modification (ICD-10-AM) codes, as detailed in  
157 Supplemental Table 1. Given that not all asthma cases are necessarily allergic,<sup>34 35</sup> and considering that  
158 our dataset encompasses the ICD code J45.9, indicative of unspecified asthma, we presented asthma  
159 both independently and collectively with allergic diseases. This approach aims to clarify both the  
160 overall burden of asthma and allergic diseases collectively, as well as specific instances.

## 161 Statistical methods

162 We described participants' characteristics using frequency with per cent. P values were calculated  
163 using Pearson's  $\chi^2$  test, except in cases where the expected cell frequency was less than 5, where  
164 Fisher's Exact test was used. The incidence rates, with 95% confidence intervals (CIs), assuming a  
165 Poisson distribution, were calculated as the number of new asthma and allergic disease-related ED  
166 presentations per year divided by the total population of Central Queensland at risk during the same  
167 period. The total population of Central Queensland at risk per year was estimated as the total  
168 population of Central Queensland as reported by the Australian Bureau of Statistics.<sup>36</sup> The comparison  
169 of incidence and trends of asthma and allergic disease-related ED presentations over time was  
170 assessed using Poisson regression, presented as incidence rate ratios (IRRs) with corresponding 95%  
171 CIs. We used the goodness-of-fit chi-squared test to assess whether the Poisson model adequately fit  
172 our data. All P-values for these tests were not statistically significant (data not presented), suggesting  
173 that the Poisson model reasonably fits the observed data. Incidence rates specific to overall,  
174 indigenous status, and other available covariates, as described above, were presented.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Patient and public involvement**

Patients and/or the general public were not involved in the design, or conduct, or drafting of this secondary analysis.

**Results**

There were a total of 813,112 ED presentations between January 2018 and November 2023, ranging from 1,248 (0.1%) in Baralaba to 303,138 (37.3%) in Rockhampton (Supplemental Table 2).

**Background characteristics of patients presenting with asthma and allergic diseases**

Table 1 presents the background characteristics of patients presenting to the ED due to asthma and allergic diseases. Statistically significant differences were observed in overall asthma and allergic disease-related ED presentations compared to presentations for other reasons, with a higher proportion of asthma and allergic disease-related ED presentations among females, children aged between 5-14, children aged under five, and across various hospital catchment areas (Table 1).

**Incidence rates of asthma and allergic disease-related ED presentations**

Overall, the rate of asthma and allergic disease-related ED presentations was 96.9 per 10,000 person-years (95% CI: 95.3, 98.6). There was a higher rate of asthma and allergic disease-related ED presentations among the First Nations Australians, which was 177.5 per 10,000 person-years (95% CI: 169.3, 186.0), compared to the incidence rate among Australians of other descents, which was 98.9 per 10,000 person-years (95% CI: 97.2, 100.8).

Table 2 illustrates the incidence rate of the specific case between 2018 and 2023. The four most common cases presenting to emergency departments were asthma (40.5/10,000 person-years, 95% CI: 39.4, 41.5), unspecified allergy (34.6/10,000 person-years, 95% CI: 33.6, 35.6), atopic/allergic contact dermatitis (10.3/10,000 person-years, 95% CI: 9.7, 10.8) and anaphylaxis and anaphylactic shock (5.8/10,000 person-years, 95% CI: 5.4, 6.2). There was a higher incidence rate of asthma, unspecified allergy, atopic/allergic contact dermatitis and allergic urticaria among First Nations

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

199 Australians compared to Australians of other descents. No food allergy presentations were reported  
200 in our data (Table 2).

### 201 Time trend of asthma and allergic disease-related ED presentations

202 Figure 1 presents the time trend in the rates of asthma and allergic disease-related ED presentations  
203 in Central Queensland. Except for the notable increase observed between 2018 and 2019, collective  
204 asthma and allergic disease-related ED presentations among First Nations Australians remained  
205 relatively stable. These rates ranged from 132.3 per 10,000 person-year (95% CI: 115.3, 151.1) in 2018  
206 to 157.2 per 10,000 person-year in 2023 (95% CI: 138.6, 177.5;  $P=0.462$ ). Similarly, rates of asthma  
207 and allergic disease-related presentations among Australians of other descents were nearly stable,  
208 varying from 94.0 per 10000 person-year (95% CI: 89.8, 98.4) in 2018 and 88.6 per 10000 person-year  
209 (95% CI: 84.5, 92.9,  $p = 0.846$ ) in 2023.

210 Figure 2 shows the time trend of ED presentation rates related to asthma and allergic disease  
211 separately. There was a significant increase in the rate of allergic diseases among First Nations  
212 Australians over time ( $P \text{ value} = 0.026$ ). Except for the peak observed in 2019 among First Nations  
213 Australians, asthma-related ED presentations remained relatively stable over time in both First  
214 Nations Australians and Australians of other descents.

215 Table 3 presents the total incidence of asthma and allergic disease-related ED presentations over the  
216 study period by gender and age group. The incidence rate of asthma and allergic disease-related ED  
217 presentations remained stable across indigenous status, gender, and age groups, with one exception.  
218 Among children aged 4 years or younger, there was a significant decline in the overall incidence of  
219 asthma and allergic disease-related ED presentations (IRR = 0.94, 95% CI: 0.91, 0.97,  $P<0.001$ ) (Table  
220 3).

### 221 Discussion

1  
2  
3 222 To the best of our knowledge, this is the first study to examine asthma and allergic disease-related ED  
4  
5 223 presentations among both First Nations Australians and Australians of other descents in an  
6  
7 224 understudied region of Australia, which encompasses both rural and remote outback towns. There  
8  
9  
10 225 was a significant increase in the rate of allergic disease-related ED presentations among First Nations  
11  
12 226 Australians between 2018 and 2023. First Nations Australians in CQ experienced a significant rise in  
13  
14 227 allergic diseases, with higher rates of ED presentations compared to Australians of other descents.  
15  
16 228 Asthma, unspecified allergies, atopic/allergic contact dermatitis, and anaphylaxis/anaphylactic shock  
17  
18  
19 229 were the most common conditions observed in the ED presentations, with higher rates among First  
20  
21 230 Nations Australians compared to Australians of other descents.  
22  
23  
24 231 The higher rate of ED presentations related to allergic disease among First Nations Australians was  
25  
26 232 surprising given that allergic and atopic diseases have not been traditionally recognised as an  
27  
28 233 important concern among First Nations Australians.<sup>37</sup> Nevertheless, there is currently a growing  
29  
30 234 recognition of this issue. Our findings highlight a substantial and potentially increasing burden of  
31  
32  
33 235 allergic disease among First Nations Australians living in a region encompassing regional, rural, and  
34  
35 236 remote outback areas. This finding is in agreement with the findings of a study conducted in Canada  
36  
37 237 and the US that showed an increased burden of allergic and atopic diseases among the Indigenous  
38  
39 238 peoples of Canada.<sup>15</sup> Other previous studies conducted in the US and Australia, while lacking specific  
40  
41  
42 239 data on First Nations populations, also documented the existence of racial, ethnic, and socioeconomic  
43  
44 240 disparities in food allergies.<sup>12-14</sup> Further studies are warranted to understand the underlying causes of  
45  
46 241 these observed disparities.  
47  
48  
49 242 There was a notable peak in recorded asthma-related ED presentations among First Nations  
50  
51 243 Australians in 2019. This could be partially attributed to the bushfires that swept across Australia in  
52  
53 244 2019–20, also known as Black Summer, as asthma was one of the primary reasons for the ED  
54  
55  
56 245 presentations. Evidence shows that the national increase in emergency presentation and  
57  
58 246 hospitalisation rates for asthma and chronic obstructive pulmonary disease (COPD) coincided with  
59  
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Enseignement Supérieur (ABES)

increased bushfire activity during the 2019–20 bushfire season.<sup>38</sup> Bushfire smoke exposure was significantly associated with an increased risk of respiratory morbidity and other health impacts.<sup>39 40</sup> The notable spike in recorded asthma-related ED presentations could also be ascribed to the notably vigorous flu season in 2019,<sup>41</sup> which is recognised as one of the triggers for an asthma attack.<sup>42</sup>

The primary reason for ED presentations was asthma, with a significantly higher incidence observed among First Nations Australians compared to Australians of other descents. Within our dataset, asthma cases could encompass both allergic and non-allergic variants. The higher incidence of asthma-related ED presentations could reflect either an increased prevalence of asthma or asthma exacerbations in First Nations Australians and/or an increased propensity of First Nations Australians to present to ED for asthma exacerbations due to socioeconomic or other factors. Literature documented that First Nations Australians were 1.6 times more likely to report having asthma in 2018–19 compared with Australians of other descents.<sup>43</sup> Another study that used birth, hospital and ED for all First Nations Australian children born between 2003 and 2012 in Western Australia reported that 2.7% of children had been hospitalised for asthma at least once between the ages of 1 and 4 years.<sup>44</sup>

The higher incidence of asthma-related ED presentation could be multifactorial including first time/unrecognised asthma, unmet medical need, unsuccessful/inadequate home management, medication non-adherence, exacerbation triggered by environmental factors, including bushfire, environmental pollution, and risky health behaviours such as smoking. Literature has documented that nearly half (47%) of the respiratory disease burden among First Nations Australians in 2018 was linked to smoking.<sup>45</sup> The lack of access to culturally appropriate asthma education and healthcare services could also contribute to the higher incidence of asthma-related ED presentations among First Nations Australians.<sup>46</sup>

Atopic/allergic contact dermatitis ranked as the third most common cause for ED visits, with a higher rate noted among First Nations Australians compared to Australians of other descents. A 5-year retrospective audit of all outpatient encounters with a visiting dermatology specialist in the Kimberley



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

region of Western Australia reported that eczema/dermatitis was the primary condition seen in First Nations Australians (19%) and third most common in Australians of other descents (17%).<sup>47</sup> Another study conducted in Melbourne between 2009 and 2011 reported that 3.9% of ED presentations were due to skin complaints, of which eczema/dermatitis was the fourth most common dermatological condition although data on the indigenous status of the study population<sup>48</sup> was not reported. It is documented that atopic dermatitis is associated with a higher risk of other atopic disorders, including asthma, hay fever, food allergy, and eosinophilic esophagitis.<sup>49</sup> It is also a known risk factor for streptococcal skin infection<sup>49-52</sup> and subsequent systemic and life-threatening complications including sepsis, endocarditis, and bone and joint infections if left untreated.<sup>49 53-55</sup> For instance, a study at the Wuchopperen Clinic in Cairns, Far North Queensland, found that 73.7% of children and youths treated for skin infections tested positive for group A streptococcus.<sup>56</sup>

We found that anaphylaxis/anaphylactic shock was the fourth most common cause of allergy related ED presentations. Previous studies conducted in Australia<sup>57 58</sup> documented an increase in the rate of anaphylaxis over time although they lack data based on indigenous status. A study conducted in Victoria reported that the causes of anaphylaxis-related ED presentations were foods (62%); drugs (12%), insect venoms (8%), and other causes (4%).<sup>59</sup> The current study lacked data to specify the causes of anaphylaxis/ anaphylactic shock. Interestingly, there were no food allergy presentations recorded in our data. However, it is possible that a substantial portion of the unspecified allergies, which was the second most frequent cause of ED presentations, may be linked to food allergies. Further studies are required to fill this evidence gap in our study area.

There was a twofold higher rate of allergic urticaria-related ED presentations, which ranked as the fifth leading cause of ED visits, among First Nations Australians compared to their counterparts. A study conducted in Italy reported that acute urticaria in 1 year accounted for 1.01% of total ED visits and 1.2 admissions per day <sup>60</sup> and drugs, insect bites, foods and contact urticaria were the most common triggers identified. With a presumption that allergic urticaria that results in ED presentation

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Enseignement Supérieur (ABES)



in our study is acute urticaria<sup>61</sup>, literature documented its risk factors including high population density,<sup>62</sup> personal<sup>63</sup> and parental history of allergic diseases,<sup>64 65</sup> poverty and lower socio-economic status.<sup>62 66</sup> Further studies are required to understand risk factors associated with allergic urticaria, particularly among First Nations Australians.

Strengths of the study include the use of the most recent, large data set including both First Nations Australians and Australians of other descents and all age groups from a study setting encompassing regional, rural, and remote outback areas. As a limitation, the reporting of ED presentations related to asthma and allergic disease relies on the ICD codes entered by physicians at the time of presentation. Our study specifically focused on asthma and allergic disease-related ED presentations and did not encompass all instances of acute asthma and allergic diseases in the general population which may visit health facilities in routes other than ED. Caution should be taken when generalising our results to the broader population, as they may not fully reflect the overall incidence of asthma and allergic diseases in the community but asthma and acute allergic disease resulting in ED visits only. Our analyses were limited to factors available in the administrative data, not comprehensively incorporating other important factors, including socioeconomic status, which encompasses education, financial resources, social standing, access to transportation, mobile phones, the internet, housing conditions, and geographic location,<sup>67</sup> comorbidities, time of first allergy diagnosis, family history of allergies, obesity/overweight, smoking status, and environmental factors among others. For instance, literature has documented that social disadvantage impacts many aspects of allergic disease, including healthcare access, prevalence, and outcomes.<sup>12 68</sup> Therefore, further research is needed to explore the overall incidence of asthma and allergic diseases, considering a comprehensive set of potential confounders, to provide a more thorough understanding of both overall allergy incidence and its associated factors. Also, it is important to note that our study relied on the accurate reporting of individuals' indigenous status in medical records.

## Conclusion

1  
2  
3 322 Our findings highlight a significantly higher rate of asthma and allergic disease-related ED  
4  
5 323 presentations among First Nations Australians compared to Australians of other descents in Central  
6  
7 324 Queensland. This underscores the urgent need for further research to understand the causality and  
8  
9  
10 325 targeted healthcare interventions integrating a culturally sensitive approach.

11  
12  
13 326 **Acknowledgements**

14  
15  
16 327 We express our gratitude to Central Queensland Hospital and Health Service (CQHHS) for granting us  
17  
18 328 permission to use routinely collected hospital administrative data for our further analysis.

19  
20  
21 329 **Contributors**

22  
23  
24 330 All authors (DMS, MHA, DM, RW, PDS, CFM, RLP, GK, JJK) contributed to the design of the study and  
25  
26 331 the interpretation of data. DMS performed the data analysis and drafted the manuscript. All authors  
27  
28 332 (DMS, MHA, DM, RW, PDS, CFM, RLP, GK, JJK) read, revised, and approved the final manuscript. DMS  
29  
30 333 acted as the guarantor.

31  
32  
33 334 **Funding**

34  
35  
36 335 DMS is supported by a Postdoctoral Fellowship funded through the Centre for Food Allergy Research  
37  
38 336 Centre of Research Excellence (CFAR3 2023-2028\_NH&MRC GNT 2015724). PDS (GRT1193840), R.L.P.  
39  
40 337 (GNT1160779), G.K. (2021/GNT2009873), and J.J.K. (GNT1158699) are supported by NHMRC-funded  
41  
42 338 fellowships. This study received no grant from any funding agency in public, commercial or not-for-  
43  
44 339 profit domains.

45  
46  
47  
48 340 **Competing interests**

49  
50  
51 341 All other authors have no competing interest to declare.

52  
53  
54 342 **Patient consent for publication**

55  
56  
57 343 Not required.

58  
59  
60 344 **Ethics approval**

345 We obtained ethics approval from the Human Research Ethics Committee (HREC) of the Central  
346 Queensland Hospital and Health Service (CQHHS) (Reference Id: 101806). Owing to the retrospective  
347 design of this study and its reliance on routinely collected hospital administrative data for medical  
348 services, seeking individual consent was deemed unnecessary.

#### 349 **Data availability statement**

350 Data are not publicly available and may be obtained from a third party. Deidentified patient data can  
351 be requested from the Central Queensland Hospital and Health Service (CQHHS).

#### 352 **ORCID iDs**

353 Desalegn Markos Shifti: <https://orcid.org/0000-0001-6638-6194>

References

1. Tanno LK, Demoly P. Allergy in the World Health Organization's International Classification of Diseases (ICD)-11. *Pediatric Allergy and Immunology* 2022;33:5-7.

2. WHO. Noncommunicable diseases [cited 11 April 2024]. Available from: <https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases> accessed 2024 11 April.

3. Cook M, Douglass J, Mallon D, et al. The economic impact of allergic disease in Australia: not to be sneezed at. *ASCIA/Access Economics Report* 2007

4. Vale SL, Said M, Smith J, et al. Welcome back Kotter—developing a national allergy strategy for Australia. *World Allergy Organization Journal* 2022;15(11):100706.

5. Nunes C, Pereira AM, Morais-Almeida M. Asthma costs and social impact. *Asthma research and practice* 2017;3:1-11.

6. Papadopoulos NG, Agache I, Bavbek S, et al. Research needs in allergy: an EAACI position paper, in collaboration with EFA. *Clinical and translational allergy* 2012;2(1):1-23.

7. Parliament of Australia. Overview of allergies and anaphylaxis in Australia [cited 15 January 2024]. Available from: [https://www.aph.gov.au/Parliamentary\\_Business/Committees/House/Health\\_Aged\\_Care\\_and\\_Sport/Allergiesandanaphylaxis/Report/section?id=committees%2Freportrep%2F024422%2F72559](https://www.aph.gov.au/Parliamentary_Business/Committees/House/Health_Aged_Care_and_Sport/Allergiesandanaphylaxis/Report/section?id=committees%2Freportrep%2F024422%2F72559) accessed 2024 15 January.

8. Bosnic-Anticevich S, Smith P, Abramson M, et al. Impact of allergic rhinitis on the day-to-day lives of children: insights from an Australian cross-sectional study. *BMJ open* 2020;10(11):e038870.

9. McDonald VM, Hiles SA, Jones KA, et al. Health-related quality of life burden in severe asthma. *Medical Journal of Australia* 2018;209(S2):S28-S33.

10. Gupta R, Holdford D, Bilaver L, et al. The economic impact of childhood food allergy in the United States. *JAMA pediatrics* 2013;167(11):1026-31.

- 381 11. Hua X, Dalziel K, Brettig T, et al. Out-of-hospital health care costs of childhood food allergy in  
 382 Australia: A population-based longitudinal study. *Pediatric Allergy and Immunology*  
 383 2022;33(11):e13883.
- 384 12. Jiang J, Warren CM, Brewer A, et al. Racial, Ethnic, and Socioeconomic Differences in Food  
 385 Allergies in the US. *JAMA Network Open* 2023;6(6):e2318162-e62.
- 386 13. Suaini NH, Loo EXL, Peters RL, et al. Children of Asian ethnicity in Australia have higher risk of  
 387 food allergy and early-onset eczema than those in Singapore. *Allergy* 2021;76(10):3171-82.
- 388 14. Panjari M, Koplin J, Dharmage S, et al. Nut allergy prevalence and differences between  
 389 Asian-born children and Australian-born children of Asian descent: a state-wide survey of  
 390 children at primary school entry in Victoria, Australia. *Clinical & Experimental Allergy*  
 391 2016;46(4):602-09.
- 392 15. Jafri S, Janzen J, Kim R, et al. Burden of allergic disease in racial and ethnic structurally oppressed  
 393 communities within Canada and the United States: a scoping review. *The Journal of Allergy*  
 394 *and Clinical Immunology: In Practice* 2022;10(11):2995-3001.
- 395 16. Ahmed A, Hakim A, Becker A. Evaluation of eczema, asthma, allergic rhinitis and allergies among  
 396 the grade-1 children of Iqaluit. *Allergy, Asthma & Clinical Immunology* 2018;14:1-14.
- 397 17. Australian Government Department of Health and Aged care. Status and determinants of  
 398 Aboriginal and Torres Strait Islander health [cited 17 January 2024]. Available from:  
 399 [https://www.health.gov.au/topics/aboriginal-and-torres-strait-islander-health/status-and-](https://www.health.gov.au/topics/aboriginal-and-torres-strait-islander-health/status-and-determinants)  
 400 [determinants](https://www.health.gov.au/topics/aboriginal-and-torres-strait-islander-health/status-and-determinants) accessed 2024 17 January.
- 401 18. Stephens C, Nettleton C, Porter J, et al. Indigenous peoples' health—why are they behind  
 402 everyone, everywhere? *The Lancet* 2005;366(9479):10-13.
- 403 19. ABS. National Aboriginal and Torres Strait Islander Health Survey: Statistics about long-term  
 404 health conditions, disability, lifestyle factors, physical harm and use of health services, 2018-  
 405 19 [cited 18 January 2024]. Available from:  
 406 <https://www.abs.gov.au/statistics/people/aboriginal-and-torres-strait-islander->

1  
2  
3 407 [peoples/national-aboriginal-and-torres-strait-islander-health-survey/latest-release](#) accessed  
4  
5 408 2024 18 January.  
6  
7  
8 409 20. AIHW. First Nations people with asthma [cited 18 January 2024]. Available from:  
9  
10 410 [https://www.aihw.gov.au/reports/chronic-respiratory-conditions/first-nations-people-with-](https://www.aihw.gov.au/reports/chronic-respiratory-conditions/first-nations-people-with-asthma)  
11  
12 411 [asthma](#).  
13  
14 412 21. AIHW. Chronic respiratory conditions: First Nations people with Asthma [cited 04 April 2024].  
15  
16 413 Available from: <https://www.aihw.gov.au/reports/chronic-respiratory-conditions/asthma>  
17  
18 414 accessed 2024 04 April.  
19  
20  
21 415 22. Courtney A, Lopez DJ, Lowe AJ, et al. Burden of disease and unmet needs in the diagnosis and  
22  
23 416 management of atopic dermatitis in diverse skin types in Australia. *Journal of Clinical*  
24  
25 417 *Medicine* 2023;12(11):3812.  
26  
27  
28 418 23. AIHW. Profile of First Nations people [cited 17 January 2024]. Available from:  
29  
30 419 <https://www.aihw.gov.au/reports/australias-welfare/profile-of-indigenous-australians>  
31  
32 420 accessed 2024 17 January.  
33  
34 421 24. Botha M, Basera W, Facey-Thomas HE, et al. Rural and urban food allergy prevalence from the  
35  
36 422 South African Food Allergy (SAFFA) study. *Journal of Allergy and Clinical Immunology*  
37  
38 423 2019;143(2):662-68. e2.  
39  
40  
41 424 25. Allen KJ, Koplin JJ. What can urban/rural differences in food allergy prevalence tell us about the  
42  
43 425 drivers of food allergy? *Journal of Allergy and Clinical Immunology* 2019;143(2):554-56.  
44  
45 426 26. Osborne NJ, Ukoumunne OC, Wake M, et al. Prevalence of eczema and food allergy is associated  
46  
47 427 with latitude in Australia. *Journal of allergy and clinical immunology* 2012;129(3):865-67.  
48  
49  
50 428 27. Khan A, Green K, Smoll N, et al. Roles, experiences and perspectives of the stakeholders of  
51  
52 429 “10,000 Lives” smoking cessation initiative in Central Queensland: Findings from an online  
53  
54 430 survey during COVID-19 situation. *Health Promotion Journal of Australia* 2022;33:316-26.  
55  
56  
57 431 28. Australian Bureau of Statistics. Digital boundary files; Australian Statistical Geography Standard  
58  
59 432 (ASGS) Edition 3. Reference period July 2021 - June 2026. [Available from:

- 433 <https://www.abs.gov.au/statistics/standards/australian-statistical-geography-standard-asgs->  
 434 [edition-3/jul2021-jun2026/access-and-downloads/digital-boundary-files](https://www.abs.gov.au/statistics/standards/australian-statistical-geography-standard-asgs-edition-3/jul2021-jun2026/access-and-downloads/digital-boundary-files) accessed 2024 31  
 435 May.
- 436 29. Queensland Government. Central Queensland region [cited 23 January 2024]. Available from:  
 437 [https://teach.qld.gov.au/teach-in-queensland-state-schools/our-schools/central-](https://teach.qld.gov.au/teach-in-queensland-state-schools/our-schools/central-queensland-region)  
 438 [queensland-region](https://teach.qld.gov.au/teach-in-queensland-state-schools/our-schools/central-queensland-region) accessed 2024 23 January.
- 439 30. Queensland Government. Central Queensland Hospital and Health Service: Queensland Health;  
 440 2016 [Available from: <https://www.health.qld.gov.au/cq> accessed 26/01/2019 2019.
- 441 31. Australian Government, Department of Health and Aged care. Health Workforce Locator [cited  
 442 08 March 2024]. Available from: [https://www.health.gov.au/resources/apps-and-](https://www.health.gov.au/resources/apps-and-tools/health-workforce-locator/app)  
 443 [tools/health-workforce-locator/app](https://www.health.gov.au/resources/apps-and-tools/health-workforce-locator/app) accessed 2024 08 March.
- 444 32. Australian Bureau of Statistics. Central Queensland: Australian Bureau of Statistics; 2022  
 445 [Available from: [https://www.abs.gov.au/census/find-census-](https://www.abs.gov.au/census/find-census-data/quickstats/2021/3082023)  
 446 [data/quickstats/2021/3082023](https://www.abs.gov.au/census/find-census-data/quickstats/2021/3082023).
- 447 33. Queensland Health. Terminology Guide: for the use of 'First Nations' and 'Aboriginal' and  
 448 'Torres Strait Islander' peoples references [cited 09 April 2024]. Available from:  
 449 [https://www.health.qld.gov.au/\\_data/assets/pdf\\_file/0031/147919/terminology.pdf](https://www.health.qld.gov.au/_data/assets/pdf_file/0031/147919/terminology.pdf)  
 450 accessed 2024 09 April.
- 451 34. Romanet-Manent S, Charpin D, Magnan A, et al. Allergic vs nonallergic asthma: what makes the  
 452 difference? *Allergy* 2002;57(7):607-13.
- 453 35. Johansson S, Hourihane JB, Bousquet J, et al. A revised nomenclature for allergy: an EAACI  
 454 position statement from the EAACI nomenclature task force. *Allergy* 2001;56(9):813-24.
- 455 36. Australian Bureau of Statistics. Central Queensland: 2021 Census All persons QuickStats [cited 30  
 456 January 2024]. Available from: [https://www.abs.gov.au/census/find-census-](https://www.abs.gov.au/census/find-census-data/quickstats/2021/308)  
 457 [data/quickstats/2021/308](https://www.abs.gov.au/census/find-census-data/quickstats/2021/308) accessed 2024 30 January.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

37. Valery PC, Masters IB, Chang A. Asthma is not prevalent in Aboriginal and Torres Strait Islander children: a myth. *Journal of Paediatrics and Child Health* 2002;38(1):105-06.

38. AIHW. Data update: Short-term health impacts of the 2019–20 Australian bushfires [cited 16 January 2024]. Available from: <https://www.aihw.gov.au/reports/environment-and-health/data-update-health-impacts-2019-20-bushfires/contents/about> accessed 2024 16 January

39. Liu JC, Pereira G, Uhl SA, et al. A systematic review of the physical health impacts from non-occupational exposure to wildfire smoke. *Environmental research* 2015;136:120-32.

40. Asthma Australia. Bushfire Smoke Impacts Survey 2019-2020- Bushfire Smoke: Are You Coping? 2020

41. Adegbija O, Walker J, Smoll N, et al. Notifiable diseases after implementation of COVID-19 public health prevention measures in Central Queensland, Australia. *Communicable diseases intelligence (2017: Online)* 2021

42. Papadopoulos NG, Christodoulou I, Rohde G, et al. Viruses and bacteria in acute asthma exacerbations—A GA2LEN-DARE\* systematic review. *Allergy* 2011;66(4):458-68.

43. AIHW. Chronic respiratory conditions: Asthma [cited 16 January 2024]. Available from: <https://www.aihw.gov.au/reports/chronic-respiratory-conditions/asthma> accessed 2024 16 January.

44. Brew B, Gibberd A, Marks GB, et al. Identifying preventable risk factors for hospitalised asthma in young Aboriginal children: a whole-population cohort study. *Thorax* 2021;76(6):539-46.

45. AIHW. Australian Burden of Disease Study: Impact and causes of illness and death in Aboriginal and Torres Strait Islander people 2018. *Canberra: AIHW* 2022

46. Brock C, McGuane J. Determinants of asthma in Indigenous Australians: insights from epidemiology. *Austr Indigenous Health Bulletin* 2018;18(2):12-20.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).



47. Haggett MG, Tait CP. Five years of dermatological disease requiring specialist care in the Kimberley region of Western Australia. *Australasian Journal of Dermatology* 2021;62(2):157-61.
48. Lai-Kwon J, Weiland TJ, Chong AH, et al. Which dermatological conditions present to an emergency department in Australia? *Emergency Medicine International* 2014;2014
49. Silverberg JI. Comorbidities and the impact of atopic dermatitis. *Annals of Allergy, Asthma & Immunology* 2019;123(2):144-51.
50. Alexander H, Paller A, Traidl-Hoffmann C, et al. The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group. *British Journal of Dermatology* 2020;182(6):1331-42.
51. Sugarman JL, Hersh AL, Okamura T, et al. A retrospective review of streptococcal infections in pediatric atopic dermatitis. *Pediatric dermatology* 2011;28(3):230-34.
52. Brook I, Frazier EH, Yeager JK. Microbiology of infected atopic dermatitis. *International journal of dermatology* 1996;35(11):791-93.
53. Benenson S, Zimhony O, Dahan D, et al. Atopic dermatitis—a risk factor for invasive *Staphylococcus aureus* infections: two cases and review. *The American Journal of Medicine* 2005;118(9):1048-51.
54. Patel D, Jahnke MN. Serious complications from *Staphylococcus aureus* in atopic dermatitis. *Pediatric dermatology* 2015;32(6):792-96.
55. Serrano L, Patel KR, Silverberg JI. Association between atopic dermatitis and extracutaneous bacterial and mycobacterial infections: a systematic review and meta-analysis. *Journal of the American Academy of Dermatology* 2019;80(4):904-12.
56. Valery PC, Wenitong M, Clements V, et al. Skin infections among Indigenous Australians in an urban setting in far North Queensland. *Epidemiology & Infection* 2008;136(8):1103-08.
57. Mullins RJ, Dear KB, Tang ML. Time trends in Australian hospital anaphylaxis admissions in 1998-1999 to 2011-2012. *Journal of Allergy and Clinical Immunology* 2015;136(2):367-75.

1  
2  
3 508 58. Stiles SL, Sanfilippo FM, KS RL, et al. Contemporary trends in anaphylaxis burden and healthcare  
4  
5 509 utilisation in Western Australia: A linked data study. *World Allergy Organization Journal*  
6  
7 510 2023;16(9):100818.  
8  
9  
10 511 59. Drewett GP, Encena J, Gregory J, et al. Anaphylaxis in Victoria: presentations to emergency  
11  
12 512 departments, with a focus on drug-and antimicrobial-related cases. *Medical Journal of*  
13  
14 513 *Australia* 2022;216(10):520-24.  
15  
16 514 60. Losappio L, Heffler E, Bussolino C, et al. Acute urticaria presenting in the emergency room of a  
17  
18 515 general hospital. *European Journal of Internal Medicine* 2014;25(2):147-50.  
19  
20  
21 516 61. Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international  
22  
23 517 EAACI/GA<sup>2</sup>LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis,  
24  
25 518 and management of urticaria. *Allergy* 2022;77(3):734-66.  
26  
27  
28 519 62. Jadhav R, Alcalá E, Sirota S, et al. Risk factors for acute urticaria in Central California.  
29  
30 520 *International Journal of Environmental Research and Public Health* 2021;18(7):3728.  
31  
32 521 63. Thomsen SF, Van der Sluis S, Kyvik KO, et al. Urticaria in monozygotic and dizygotic twins. *Journal*  
33  
34 522 *of allergy* 2012;2012  
35  
36 523 64. Hu Y, Chen Y, Liu S, et al. Breastfeeding duration modified the effects of neonatal and familial risk  
37  
38 524 factors on childhood asthma and allergy: a population-based study. *Respiratory research*  
39  
40 525 2021;22(1):1-11.  
41  
42  
43 526 65. Kolkhir P, Giménez-Arnau AM, Kulthanan K, et al. Urticaria. *Nature Reviews Disease Primers*  
44  
45 527 2022;8(1):61.  
46  
47  
48 528 66. Gabrielle P, Hashim MJ, Shaughnessy C, et al. Global epidemiology of urticaria: increasing burden  
49  
50 529 among children, females and low-income regions. *Acta Dermato-Venereologica* 2021;101(4)  
51  
52 530 67. Australian Indigenous HealthInfoNet. Summary of respiratory diseases among Aboriginal and  
53  
54 531 Torres Strait Islander children *Perth, WA Australian Indigenous HealthInfoNet*  
55  
56 532 *healthinfoNetCueDuau/respiratory* 2022  
57  
58  
59  
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Enseignement Supérieur (ABES)

- 1  
2  
3 533 68. Perry TT, Grant TL, Dantzer JA, et al. Impact of socioeconomic factors on allergic diseases. *Journal*  
4  
5 534 *of Allergy and Clinical Immunology* 2023  
6  
7  
8 535  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Enseignement Supérieur (ABES).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Figure Legends**

**Figure 1.** Incidence of both asthma and allergic disease-related Emergency Department presentations in Central Queensland between 2018 and 2023  
ED= Emergency Department

**Figure 2.** Separate incidence of asthma and allergic disease-related Emergency Department presentations in Central Queensland between 2018 and 2023  
ED= Emergency Department

For peer review only

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Enseignement Supérieur (ABES).

**Table 1.** Background characteristics of patients presenting with asthma and allergic diseases compared to individuals presenting to ED for other reasons (N=813112)

Variable	Asthma and allergic disease-related ED presentations		P value
	No	Yes	
Indigenous status (n=812995)			
First Nations Australians	107099 (98.4)	1755 (1.6)	0.569
Australians of other descent	692623 (98.4)	11518 (1.6)	
/Not Stated			
Sex			
Female	397513 (98.2)	7395 (1.8)	< 0.001
Male	402219 (98.6)	5879 (1.4)	
Intersex	106 (100.0)	0 (0.0)	
Age group (Year, n=813111)			
≤4	78484 (97.5)	2018 (2.5)	< 0.001
5-14	87248 (97.2)	2540 (2.8)	
15-29	180778 (98.4)	2905 (1.6)	
30-44	148,015 (98.5)	2285 (1.5)	
45-59	129214 (98.4)	2051 (1.6)	
60+	176,098 (99.2)	1475 (0.8)	
Hospital			
Baralaba	1234(98.9)	14(1.1)	<0.001
Biloela	41009(98.0)	853(2.0)	
Blackwater	25048 (98.1)	474 (1.9)	
Emerald	83599(98.6)	1216 (1.4)	
Gladstone	203136(98.2)	3618(1.8)	
Mount Morgan	15972(98.1)	301(1.9)	
Moura	12457(98.1)	241(1.9)	
Rockhampton	298827(98.6)	4311(1.4)	
Springsure	7983(98.2)	144(1.8)	
Theodore	1414(98.7)	19(1.3)	
Woorabinda	12894(98.2)	239(1.8)	
Yeppoon	96265(98.1)	1844(1.9)	

ED= Emergency Department

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 2.** Incidence rate of asthma and allergic diseases from 2018 to 2023.

Asthma and allergic diseases	Asthma and specific type of allergy (per 10000 person-year with 95% CI)		
	First Nations Australians	Australians of other descent	Overall
Asthma*	87.8 (82.0, 93.8)	40.2 (39.0, 41.3)	40.5 (39.4, 41.5)
Unspecified allergy*	55.3 (50.8, 60.2)	36.0 (34.9, 37.1)	34.6 (33.6, 35.6)
Atopic/allergic contact dermatitis*	17.1 (14.6, 19.9)	10.6 (10.0, 11.2)	10.3 (9.7, 10.8)
Anaphylaxis and anaphylactic shock	7.2 (5.6, 9.1)	6.2 (5.7, 6.6)	5.8 (5.4, 6.2)
Allergic urticaria*	4.0 (2.9, 5.5)	2.3 (2.1, 2.6)	2.3 (2.0, 2.5)
Allergic conjunctivitis*	3.6 (2.5, 5.0)	2.4 (2.1, 2.7)	2.3 (2.1, 2.6)
Allergic rhinitis*	1.9 (1.2, 3.0)	0.7 (0.6, 0.9)	0.8 (0.6, 0.9)
Allergic purpura	0.5 (0.2, 1.2)	0.5 (0.4, 0.7)	0.5 (0.4,0.6)
Overall allergic diseases*, **	89.7 (83.9, 95.8)	58.8 (57.4, 60.2)	56.4 (55.2, 57.7)


\*P value < 0.05 when comparing the incidence rate per person-year between First Nations Australians and Australians of other descent, \*\*Overall allergic diseases encompass all specific allergic diseases, including unspecified allergy, atopic/allergic contact dermatitis, anaphylaxis, and anaphylactic shock, allergic urticaria, allergic conjunctivitis, allergic rhinitis, and allergic purpura but not asthma

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).


**Table 3.** Incidence of asthma and allergic disease-related ED presentations (per 10,000 person-years) from 2018 to 2023


Year	Asthma and allergic disease-related ED presentations							
	Sex*		Age (Year)					
	Female	Male	0-4	5-14	15-29	30-44	45-59	60+
2018	101.2	78.2	281.6	111.9	99.0	75.0	64.5	47.9
2019	116.7	89.4	262.6	147.8	119.0	77.5	82.5	55.4
2020	105.4	80.7	208.9	105.0	108.9	98.3	80.5	44.7
2021	123.6	97.2	240.7	134.2	138.5	100.1	95.3	57.0
2022	111.9	86.9	222.3	134.2	135.6	84.2	74.5	46.3
2023	96.6	76.9	208.2	133.0	97.4	76.6	60.9	44.5
IRR (95% CI)	0.99 (0.95, 1.04)	1.001 (0.951, 1.053)	0.94 (0.91, 0.97)	1.02 (0.97, 1.06)	1.02 (0.97, 1.06)	1.01 (0.96, 1.06)	0.98 (0.93, 1.04)	0.98 (0.91, 1.05)
P value	0.824	0.974	<0.001	0.320	0.432	0.700	0.710	0.587

ED= Emergency Department, IRR= Incidence rate ratio, CI= Confidence interval, \*Intersex is not included in this table, as no cases of asthma or allergic disease were reported, as shown in Table 1.









**Supplemental Figure 1.** Locator map of the study area.

**Source:** The map was developed using the digital boundary files from the Australian Bureau of Statistics.

**Supplemental Table 1.** ICD-10-AM codes related to allergic conditions.

Condition	ICD-10-AM Code
Allergy, unspecified	T78.4, Z91.0
Allergic atopic dermatitis	L20, L20.8, L20.9
Allergic contact dermatitis	L23, L23.0-L23.9
Allergic conjunctivitis	H10.1, H10.2, H10.3, H10.4,
Allergic gastroenteritis	K52.2
Allergic purpura	D69.0
Allergic rhinitis	J30, J30.1, J30.2, J30.3, J30.4, J30.5
Allergic urticaria	L50.0, L50.8
Anaphylaxis	T78.0, T78.1, T78.2, T80.5, T88.6
Asthma	J45.0, J45.8, J45.9, J46
Food allergy	Y37.0-Y37.9, Y37.2, Y37.20, Y37.21, Y37.22, Y37.23, Y37.29, Y37.3, Y37.30, Y37.31, Y37.32, Y37.39, Y37.4, Y37.5

**Supplemental Table 2.** Emergency Department presentations at Public Hospitals in Central Queensland, 1 January 2018 to 30 November 2023 (N=813, 122)

Hospital	Year Frequency (%)						Total
	2018	2019	2020	2021	2022	2023	
Baralaba	X	X	X	237 (19.0)	547 (43.8)	464 (37.2)	1248 (100.0)
Biloela	6549 (15.6)	6394 (15.3)	7312 (17.5)	7268 (17.4)	7294 (17.4)	7045 (16.8)	41862 (100.0)
Blackwater	1207 (4.7)	5184 (20.3)	4453 (17.5)	4651 (18.2)	4752 (18.6)	5275 (20.7)	25522 (100.0)
Emerald	12320 (14.5)	13129 (15.5)	13110 (15.5)	16036 (18.9)	15639 (18.4)	1458 (17.2)	84815 (100.0)
Gladstone	31065 (15.0)	34340 (16.6)	36627 (17.7)	36349 (17.6)	36209 (17.5)	32164 (15.6)	206754 (100.0)
Mount Morgan	805 (4.9)	2925 (18.0)	2820 (17.3)	3280 (20.2)	3448 (21.2)	2995 (18.4)	16273 (100.0)
Moura	481 (3.8)	2158 (17.0)	2410 (19.0)	3118 (24.5)	2603 (20.5)	1928 (15.2)	12698 (100.0)
Rockhampton	47270 (15.5)	50522 (16.7)	49869 (16.5)	55777 (18.4)	52708 (17.4)	46992 (15.5)	303138 (100.0)
Springsure	337 (4.1)	1565 (19.3)	1697 (20.9)	1644 (20.2)	1535 (18.9)	1349 (16.6)	8127 (100.0)
Theodore	X	X	X	290 (20.2)	586 (40.9)	557 (38.9)	1433 (100.0)
Woorabinda	380 (2.9)	2107 (16.0)	2497 (19.0)	2476 (18.9)	2903 (22.1)	2770 (21.1)	13133 (100.0)
Yeppoon	14540 (14.8)	15017 (15.3)	15500 (15.8)	19797 (20.2)	17577 (17.9)	15678 (16.0)	98109 (100.0)
Total	114954 (14.1)	133341 (16.4)	136295 (16.8)	150923 (18.6)	145801 (17.9)	131798 (16.2)	813112 (100.0)

X= ED services were not available.